Review

The Diverse Roles of microRNAs at the Host–Virus Interface

Annie Bernier 1 and Selena M. Sagan 1,2,*

1 Department of Microbiology & Immunology, McGill University, Montréal, QC H3G 1Y6, Canada; Annie.bernier@mail.mcgill.ca
2 Department of Biochemistry, McGill University, Montréal, QC H3G 1Y6, Canada
* Correspondence: selena.sagan@mcgill.ca

Received: 1 August 2018; Accepted: 17 August 2018; Published: 19 August 2018

Abstract: MicroRNAs (miRNAs) are small, non-coding RNAs that regulate gene expression at the post-transcriptional level. Through this activity, they are implicated in almost every cellular process investigated to date. Hence, it is not surprising that miRNAs play diverse roles in regulation of viral infections and antiviral responses. Diverse families of DNA and RNA viruses have been shown to take advantage of cellular miRNAs or produce virally encoded miRNAs that alter host or viral gene expression. MiRNA-mediated changes in gene expression have been demonstrated to modulate viral replication, antiviral immune responses, viral latency, and pathogenesis. Interestingly, viruses mediate both canonical and non-canonical interactions with miRNAs to downregulate specific targets or to promote viral genome stability, translation, and/or RNA accumulation. In this review, we focus on recent findings elucidating several key mechanisms employed by diverse virus families, with a focus on miRNAs at the host–virus interface during herpesvirus, polyomavirus, retroviruses, pestivirus, and hepacivirus infections.

Keywords: microRNAs; Herpesviruses; polyomaviruses; retroviruses; pestiviruses; hepaciviruses; latency; immune evasion; viral RNA accumulation

1. Introduction

MicroRNAs (miRNAs) are small non-coding RNA molecules, typically 21 to 25 nucleotides (nt) in length, that are highly evolutionarily conserved, developmentally regulated and are expressed in a tissue-specific manner. Since their description in the early 1990s, miRNAs have been found in over 200 species, with over 2000 human miRNAs and more than 24,000 entries in the Sanger database [1,2]. MiRNAs are typically transcribed by RNA polymerase II as long, highly structured primary miRNA transcripts (pri-miRNAs), often found in the introns of protein-coding genes [3,4]. These pri-miRNAs are then processed into short, ~70 nt hairpin-shaped precursor miRNAs (pre-miRNAs) by Drosha, a nuclear RNase III enzyme [5]. In the cytoplasm, the pre-miRNAs are further processed by the RNase III enzyme, Dicer, into mature ~22-nt miRNA duplexes [6–8]. Dicer interacts with the transactivation response RNA-binding protein (TRBP) and the protein activator of PKR (PACT), two dsRNA-binding proteins that play roles in miRNA processing efficiency and specificity [9]. Following Dicer cleavage, the mature miRNA is loaded into an Argonaute (Ago) protein, an essential component of the RNA-induced silencing complex (RISC) [10]. The Ago protein unwinds the mature miRNA duplex and uses one strand, known as the guide strand, to target miRNAs in a sequence-specific manner. While miRNAs usually bind to the 3′ untranslated region (UTR) of their target miRNAs, they have also been reported to target the 5′ UTR and coding sequences of miRNAs [11–13]. Although both strands of a duplex can serve as the guide strand, strand selection is determined by the duplex stability at the 5′ end of each miRNA arm, and highly abundant
miRNAs typically originate more frequently from the 5p strand than the 3p strand [14,15]. Pairing interactions between miRNAs and their target RNAs primarily involve nucleotides 2–8 of the miRNA, which is referred to as the “seed sequence” [16]. However, additional pairing to the 3′ region of the miRNA can compensate for mismatches in the seed region [17]. Perfect complementarity or extensive centered pairing results in target mRNA cleavage, whereas imperfect base-pairing typically results in translational inhibition and/or accelerated deadenylation, culminating in repression of target gene expression [18,19]. In mammals, miRNAs are typically imperfectly complementary to their targets, whereas in plants and insects they may have perfect complementarity [20]. Since miRNAs can bind to their targets with imperfect complementarity, a single miRNA can target over 100 genes, and a single gene may be regulated by multiple miRNAs [21,22]. In fact, it is predicted that over two-thirds of all human genes are targeted by miRNAs [23]. Thus, it is not surprising that miRNAs are implicated in many cellular processes, including cell proliferation, differentiation, apoptosis, metabolism, host immunity, and viral infections [24–27].

MiRNA-mediated regulation of viral infection has been described in a wide variety of hosts and across both DNA and RNA virus families. Several types of interactions have been observed, including: cellular miRNAs directly targeting host or viral transcripts; evasion of cellular miRNAs; broad impairment of the miRNA pathway; and even virally encoded miRNAs that regulate host or viral gene expression. Such interactions have been described to play crucial roles in the regulation of viral replication, maintenance of latency and/or reactivation, immune evasion, and cell transformation. Herein, we highlight recent studies elucidating the role of miRNAs at the host–virus interface, with a focus on several key canonical and non-canonical miRNA interactions that contribute to viral infection and pathogenesis in a select group of well-characterized DNA and RNA viruses.

2. Herpesviruses

Herpesviruses are large dsDNA viruses that can establish lifelong infections and cycle between lytic (productive) and latent (non-productive) replication [28]. This family is divided into three subfamilies with general differences in the cell types involved: the Alphaherpesvirinae latently infect neurons; Betaherpesvirinae are found in the monocyte lineage; and Gammaherpesvirinae infect lymphocytes [29]. Clinical manifestations of herpesvirus infections can range from skin and mucosal lesions to severe malignancies and deadly encephalitis. The most well-studied herpesviruses include five common human pathogens: herpes simplex viruses type 1 and 2 (HSV-1 and HSV-2), human cytomegalovirus (HCMV), Epstein-Barr virus (EBV), and human herpesvirus 8 (HHV-8), also known as Kaposi’s sarcoma-associated herpesvirus (KSHV) [30]. The role of miRNAs in the pathogenesis of herpesvirus infection has been extensively studied and provides a good overview of both canonical and non-canonical interactions with the miRNA pathway during viral infection (reviewed in [31]).

2.1. Cellular miRNAs in Herpesvirus Infection

2.1.1. MiRNAs Implicated in Latency Maintenance

Herpesviruses are characterized by their ability to carry out lytic replication or establish latency, and several cellular miRNAs have been implicated in this process. HSV-1 latency is promoted by two cellular miRNAs, miR-101 and miR-138 (Table 1). Expression of the HSV-1 immediate early protein ICP4, a key transactivator of early and late viral genes, induces the expression of miR-101 by directly binding to and activating its promoter [32,33]. In turn, miR-101 directly downregulates expression of the mitochondrial ATP synthase subunit beta (ATP5B), a protein known to promote HSV-1 replication [34]. ATP5B depletion was shown to block HSV-1 DNA packaging and capsid maturation, presumably by limiting the energy available to complete the viral life cycle [35]. MIR-101 also downregulates the RNA-binding protein G-rich sequence factor 1 (GRSF1), whose binding to HSV-1 p40 mRNA typically enhances its expression, facilitating viral replication [33]. Therefore,
induction of miR-101 expression during HSV-1 infection downregulates both ATP5B and GRSF1 expression, consequently attenuating viral replication and preventing lytic cell death. In addition, the neuron-specific miR-138 directly downregulates the expression of another viral transactivator of lytic gene expression, ICP0. Thus, both miR-101 and miR-138 have been demonstrated to inhibit lytic gene expression and promote viral latency during HSV-1 infection [36].

Similarly, HCMV is a ubiquitous pathogen that is able to establish latent infection upon resolution of acute infection [37]. Reactivation of the HCMV lytic cycle during times of immunological stress can result in severe disease and mortality [38]. The HCMV immediate early transcript, UL112, one of the two early proteins known to initiate viral reactivation, is the direct target of three human miR-200 family members: miR-200b, miR-200c, and miR-429 (Table 1) [39]. This cluster of miRNAs is highly expressed in undifferentiated cells such as monocytes, but lost during differentiation, and this is thought to act as a switch for viral reactivation [39].

Following primary infection, EBV can also establish a latent infection in the nucleus of memory B cells. Although usually benign, EBV infections are known for their ability to transform infected cells and have been associated with many cancer types, including several lymphomas [40]. Similarly to the suggested role of the miR-200 family in HCMV reactivation, miRNAs from the miR-200 cluster have also been shown to induce EBV reactivation (Table 1) [41]. Specifically, miR-200b and miR-429 directly downregulate the expression of the two host proteins, ZEB1 and ZEB2, that repress the transcription of the EBV immediate-early transcription factor, BZFL1 [42]. Thus, miR-200b and miR-429 indirectly allow expression of BZFL1, which induces early lytic gene expression and binds to the origin of replication of the EBV genome promoting viral replication. In contrast, miRNAs are also implicated in EBV latency and expression of the viral protein EBNA1 transactivates the expression of let-7a primary transcripts during infection [43]. EBNA1 is expressed during both lytic and latent infections and is required for EBV replication as well as segregation of episomal genomes during latency [44,45]. EBNA1-mediated upregulation of let-7a results in direct downregulation of Dicer gene expression, thereby decreasing overall cellular miRNA levels and reinforcing latency [43]. EBNA1 expression also results in a significant decrease in BZFL1 expression without modulating miR-200b or miR-429 levels, suggesting that EBNA1-mediated upregulation of let-7a may reinforce latency independently of ZEB1 and ZEB2 levels.

Finally, although less is known regarding the role of cellular miRNAs in KSHV latency, miR-320d, miR-498 and miR-1258 have all been shown to bind to the 3' UTR of the KSHV replication and transcription activator (RTA) transcript (Table 1). Downregulation of this important reactivation factor results in a repression of KSHV reactivation [46,47]. Thus, by targeting both host and viral transcripts (Table 1), cellular miRNAs appear to be major regulators of latency and/or viral reactivation during infection with several human herpesviruses.
Table 1. Cellular miRNAs with putative roles in herpesvirus infection.

| Virus     | miRNA     | Targets 1 | Predicted Roles                                                | References |
|-----------|-----------|-----------|-----------------------------------------------------------------|------------|
| HSV-1     | miR-101   | ATP5B     | Blocks DNA packaging and capsid maturation                     | [34]       |
|           | GRSF1     |           | Attenuates viral replication                                   | [33]       |
| miR-138   | ICPO (v)  |           | Inhibits lytic cycle gene expression                            | [36]       |
| miR-199a  | ARHGAP21  |           | Alters Golgi function disturbing viral envelopment              | [48]       |
| miR-146a  | Complement factor H |        | Immune evasion                                                 | [49]       |
|           | Arachidonic cascade |      | Alzheimer-type neurological changes                              | [49,50]    |
| miR-23a   | IRF1      |           | Innate immune evasion                                          | [51,52]    |
| miR-649   | MALT1     |           | Innate and adaptive immune evasion                              | [53,54]    |
| miR-132   | p300      |           | Innate immune evasion                                          | [55]       |
| HCMV      | miR-200 family |        |                                                                 |            |
|           | miR-200b  | UL112 (v) | Inhibits viral reactivation                                    | [39]       |
|           | -429      |           |                                                                 |            |
|           | let-7     | Dicer     | Promotes latency                                               | [43]       |
|           | miR-190   | NR4A3     | Inhibits lytic cycle                                           | [58]       |
|           |           | TPS3INP1  | Enhances cell survival                                         | [58]       |
|           | miR-424   | SIAH1     | Inhibits apoptosis                                              | [59]       |
|           | miR-127   | BLIMP1, XBP-1 |                                                 | [60]       |
| EBV       | miR-200b, -429 |        | Reactivation of lytic cycle, viral replication                  | [41,42]    |
|           | let-7     | Dicer     | Promotes latency                                               | [43]       |
|           | miR-190   | NR4A3     | Inhibits lytic cycle                                           | [58]       |
|           |           | TPS3INP1  | Enhances cell survival                                         | [58]       |
|           | miR-424   | SIAH1     | Inhibits apoptosis                                              | [59]       |
|           | miR-127   | BLIMP1, XBP-1 |                                                 | [60]       |
| KSHV      | miR-320d, -498, -1258 |    | Inhibition of reactivation                                     | [46,47]    |
|           | miR-132   | p300      | Innate immune evasion                                          | [55]       |
|           | miR-21    | Pdcd4, PTEN| Cell migration, invasion, angiogenesis                          | [61–63]    |
|           | miR-31    | FAT4      | Cell migration                                                 | [61,64]    |
|           | miR-146a  | CXCR4     | Cell migration                                                 | [65]       |
|           | miR-221/222 cluster |       | Cell migration                                                 | [64]       |
|           | miR-30b/c | DLL4      | Angiogenesis                                                   | [66]       |

1 Viral targets are indicated (v).
2.1.2. MiRNAs Implicated in Immune Evasion

Whether latency is an immune evasion strategy or a form of tolerance is subject to some debate (reviewed in [67]). The restriction of gene expression during latency significantly reduces the abundance of viral antigens available for presentation to immune cells. However, herpesviruses have also evolved distinct strategies to more directly inhibit host immune responses using miRNAs. For example, miR-23a is upregulated during HSV-1 infection, and downregulates interferon regulatory factor 1 (IRF1) gene expression, impairing the interferon pathway and leading to innate immune evasion [51]. This also results in the downregulation of the antiviral gene RSAD2, known to limit HSV-1 replication [52]. MiR-649 further promotes HSV-1 replication by directly targeting the mucosa associated lymphoid tissue lymphoma translocation gene 1 (MALT1) [53]. Downregulation of MALT1 results in evasion of both innate and adaptive immune responses through inhibition of the NF-κB pathway [54]. Of note, miR-649 levels were shown to be downregulated following HSV-1 infection in HeLa cells, and hence its downregulation may play a role in limiting HSV-1 replication through a negative feedback loop.

Similarly, during KSHV infection, upregulation of miR-132 results in repression of interferon-stimulated genes (ISGs) by targeting an important transcriptional coactivator [55]. A similar function for miR-132 has also been described in HSV-1 and HCMV infection [55]. Thus, as these examples illustrate, cellular miRNA-directed immune evasion during herpesvirus infection mainly occurs through downregulation of key signaling proteins in antiviral immune pathways.

2.1.3. MiRNAs Implicated in Cell Cycle Control and Tumorigenesis

Cellular miRNAs are also key players in the regulation of herpesvirus-induced tumors. For example, upregulation of miR-190 expression during EBV infection directly results in downregulation of TP53INP1, leading to enhanced cell survival by inhibiting apoptosis and cell cycle arrest [58]. Furthermore, upregulation of miR-424 and miR-127 during EBV infection promotes lymphomagenesis by downregulating the tumor suppressor ubiquitin ligase SIAH1 and blocking B-cell differentiation, respectively [59,60,68]. Interestingly, the viral protein EBNA1, previously discussed for its role in promotion of the latency by inducing let-7a expression, also leads to upregulation of miR-127 [60].

Like EBV, KSHV is the etiologic cause of tumorigenesis, including Kaposi’s sarcoma, a tumor of lymphatic endothelial lineage [69]. One mechanism by which KSHV is known to induce cancer involves interleukin-6 (IL-6), a cytokine that promotes cell growth, angiogenesis and lymphoma formation. KSHV infection induces tumorigenesis through upregulation of host interleukin-6 (IL-6), a cytokine that promotes cell growth, angiogenesis, and lymphoma formation [70,71]. In addition, KSHV also encodes a viral mimic of human IL-6 (vIL-6). However, cellular miR-608 and miR-1293, respectively, can downregulate human IL-6 and vIL-6 expression directly through binding to sequences in their open reading frames (ORFs) [72]. On the other hand, the viral ORF57 protein can compete with these miRNAs for binding to these sequences on the IL-6 and vIL-6 mRNAs [73]. ORF57 binding thus masks these miRNA sites, and subsequently results in stabilization of these transcripts, promoting IL-6 and vIL-6 gene expression. Furthermore, KSHV infection results in upregulation of miR-21 and miR-31, which directly target two tumor suppressors linked to neoplastic transformation, cell migration and angiogenesis [61–64]. Upregulation of miR-146a is also implicated in KSHV-infected cell migration and spread by directly targeting the chemokine receptor CXCR4, which promotes the premature release of endothelial cell progenitors into the blood stream [65]. Of note, both miR-21 and miR-146 have been detected inside KSHV virions and were reported to retain their biological functionality during de novo infections [74]. Evidence suggests that these so-called “virional” miRNAs are selectively packaged inside virions during encapsidation or envelopment, but it is still unclear if they directly contribute to infection or pathogenesis in vivo. However, similar virional miRNAs have been reported in other viral infections, including HCMV and HIV-1, suggesting that this may be a common strategy used to control gene expression early in infection [75,76].
Thus, it is clear that herpesviruses modulate cellular miRNA expression in order to regulate latency, evade antiviral immune responses and promote tumorigenesis. The identification of virional miRNAs provides an additional layer of complexity and further research will be required to elucidate whether this provides a distinct advantage to the virus during de novo infection.

2.2. Herpesvirus-Encoded miRNAs

An important characteristic of herpesviruses that distinguishes them from many other virus families is their ability to express several virally encoded miRNAs [77,78]. Since the discovery of the first viral miRNA of EBV in 2004, more than 500 viral miRNAs have been identified across several diverse virus families [2,79,80]. To date, 8 of the 9 human herpesviruses have been shown to encode at least one miRNA [81]. These miRNAs have been reported to target both cellular and viral transcripts and play significant roles in regulating latency and evading host immune responses, both of which will be described in more detail below.

2.2.1. Viral miRNAs with Cellular Targets

Although most identified targets of the 27 mature HSV-1 miRNAs are viral transcripts, recent research has described roles for these viral miRNAs in targeting cellular transcripts to promote immune evasion, viral replication, cell proliferation, and pathogenesis [82,83]. One such example is the targeting of PIGT by miR-H8. PIGT is an important component of the glycosylphosphatidylinositol anchoring pathway that allows proteins to be presented on the cell surface. MiR-H8 represses PIGT expression resulting in a reduction in presentation of many immune-related proteins, including NK-cell ligands and the viral restriction factor, tetherin [83]. Thus, by targeting PIGT, miR-H8 efficiently counteracts the host immune response at several key points. In addition, the HSV-1 miR-H1 directly targets the ubiquitin protein ligase 3 component, Ubr1, a crucial component of the ubiquitin-proteasome system [84,85]. MiR-H1-mediated downregulation of the ubiquitin-proteosome system results in accumulation of neurodegenerative-associated protein fragments, and thus may play a role in HSV-1 pathogenesis [84].

In contrast to HSV-1, most of the 21 mature HCMV-encoded miRNAs are thought to target cellular transcripts, with well-defined roles in immune evasion from NK cell-mediated killing [31]. HCMV-miR-UL112 targets the major histocompatibility complex (MHC) class-I related chain B (MICB), a NKG2D ligand, to reduce NK-mediated killing [86]. The viral miRNA binding site overlaps with that of the cellular miR-367a, which suggests that HCMV may have evolved to prevent target site mutations by targeting highly conserved sequences [87]. Of note, EBV BART-2-5p and KSHV K-12-1 were also reported to target MHC class-I related chain A (MICA) and inhibition of NK cell proliferation and activation [89–91]. Additional roles for HCMV miRNAs have been reported in cell cycle control, regulation of latent and lytic infection, and in vesicle trafficking to support virion assembly [31,92].

EBV encodes at least 44 mature miRNAs with described roles in immune evasion, inhibition of apoptosis, cell transformation, and maintenance of latency [31,93–95]. As examples, miR-BHRF1-3 targets CXCL11, a T-cell attracting chemokine [96]; miR-BART2-5p (as discussed above) targets the NK cell ligand MICB [88]; and miR-BART6-3p downregulates the expression of the antiviral RNA helicase, retinoic acid-inducible gene I (RIG-I) [97]; all contributing to EBV-mediated evasion of host innate immune responses. On the other hand, one of the most well characterized targets of EBV miRNAs is the pro-apoptotic protein PUMA, which is downregulated by miR-BART-5p to avoid apoptosis of EBV-infected cells [98]. Targeting of at least three other pro-apoptotic genes as well as multiple tumor suppressors by several EBV miRNAs has also been reported, suggesting they contribute to EBV-induced tumorigenesis and cell transformation [31,99]. Interestingly, EBV miR-BART6-5p, may also play a critical role in maintenance of latency by directly targeting the human Dicer transcript,
resulting in repression of miRNA biogenesis and reinforcing the previously discussed strategy of let-7-mediated repression of miRNA expression during EBV infection [43,95]. Since Dicer is also required for viral miRNA processing, this suggests a negative feedback loop may tightly regulate miRNA levels. The downregulation of Dicer also results in decreased expression of EBV lytic transactivators (Zta and Rta) and EBNA2, which further reinforce latency. Thus, EBV encoded miRNAs act on host transcripts to promote both immune evasion and viral latency [100,101].

Finally, KSHV encodes at least 25 mature miRNAs that are implicated in immune evasion and tumorigenesis. Three KSHV miRNAs (miR-K12-1, -K12-6 and -K12-7) have been demonstrated to target MCP-1-induced protein 1 (MCPIP1) transcripts, a protein implicated in suppression of miRNA biosynthesis (through cleavage of pre-miRNAs) and negative regulator of inflammation through cleavage of IL-6 mRNA [102–104]. In addition, miR-K12-3 and miR-K12-7 downregulate the expression of C/EBPβ, a translational repressor of IL-6 and IL-10 [105]. Thus, combined with previously discussed effects of viral ORF57 competition for cellular miRNA target sites on expression of vIL-6 and IL-6 mRNAs, this leads to a further upregulation of IL-6 expression, further promoting cell growth, angiogenesis and lymphoma formation. These three mechanisms demonstrate how viral products, including several miRNAs, can have both cooperative and redundant functions during viral infection.

In addition to de novo targeting, three KSHV miRNAs share seed sequences with cellular miRNAs, making them functional orthologs able to tap into established cellular miRNA target networks [106–109]. Through this activity, miR-K12-10 (miR-142-3p ortholog) inhibits the TGF-β pathway to promote cell survival [110]; miR-K12-3 (miR-23 ortholog) inhibits caspases 3 and 7 to inhibit apoptosis [109]; and miR-K12-11 (miR-155 ortholog) represses several signaling pathway components of the interferon response and promotes cell survival [111–115]. Thus, KSHV modulates cellular gene expression through de novo targeting, but also uses miRNA mimicry to tap into established cellular miRNA target networks. Through these activities, KSHV miRNAs promote immune evasion, cell survival, and tumorigenesis.

2.2.2. Viral miRNAs Regulating Viral Transcripts

While cellular miRNAs play crucial roles in maintaining latency, several virally encoded miRNAs have also been shown to promote latency through targeting viral transcripts. HSV-1 miR-H6 represses expression of the viral protein ICP4, an immediate early gene that normally promotes the lytic cycle through transcriptional activation of early and late genes as well as through downregulation of LAT expression [116]. Moreover, similarly to miR-138, miR-H12 represses ICP0 expression, a viral transactivator of early gene expression [117,118]. Two other HSV-1 miRNAs have also been shown to promote latency by targeting a lytic neurovirulence factor (ICP34.5), and all four of these HSV-1 miRNAs implicated in viral latency were found to be upregulated during the latent cycle [117,119–121]. In contrast to HSV-1, very few HCMV or EBV miRNAs have been reported to target viral transcripts. However, HCMV miR-UL112-1 was shown to downregulate the major immediate early transactivator, IE72, resulting in a reduction of viral replication and promotion of latency [122]. During EBV infection, miR-BART-5p, miR-BART15 and miR-BART17-5p all downregulate expression of the viral latency-associated membrane protein, LMP1 [123]; while miR-BART22 targets LMP2A [124]. Since LMP1 and LMP2A are known viral antigens that can induce potent cytotoxic CD4+ and CD8+ T cell responses and NF-κB signaling, their downregulation by EBV miRNAs is predicted to play a role in both latency maintenance and immune evasion [123,125,126].

Like HSV-1, KSHV miRNAs that target viral transcripts have well-described roles in the maintaining latency (reviewed in [127]). This role is in accordance with their location in the viral genome as all KSHV miRNAs are encoded within the latency-associated region [128]. MiR-K12-7 and miR-K12-9 both directly downregulate the viral protein RTA, a protein essential for initiation of lytic replication [129,130]. In addition, several other KSHV miRNAs indirectly inhibit RTA expression, by silencing the RTA promoter or repressing known RTA activators [131,132]. Taken together, the majority
of herpesvirus miRNAs that target viral transcripts appear to play important roles in latency maintenance. However, although viral targets have not been confirmed for the vast majority of herpesvirus miRNAs, their differential expression during latent and lytic cycles suggest additional as of yet unidentified roles for these miRNAs in regulation of latency [133].

In summary, while the targets of herpesvirus-encoded miRNAs are still being elucidated, it is clear that these miRNAs play a major role in regulating gene expression in infected cells. Through their cellular targets, herpesvirus miRNAs promote immune evasion, cell survival and tumorigenesis; while the viral targets appear to be crucial for latency maintenance. The variety of diverse mechanisms utilized by herpesviruses, including broad regulation of the miRNA pathway, virally encoded miRNAs and miRNA mimicry, is likely a reflection of the long co-evolution of herpesviruses with the miRNA pathway.

3. Polyomaviruses

Polyomaviruses (PyVs) are non-enveloped viruses with a circular dsDNA genome of ~5 kb [134, 135]. The PyV family includes >70 species classified in 4 genera that infect a wide range of hosts including humans, primates, birds, rodents, and cattle [136]. Although most infections by PyVs are asymptomatic, PyV infection increases the overall incidence of tumor formation (reviewed in [137]). The PyV family shares a similar genomic organization in which the genome is divided into an early and late region encoded on opposite strands (Figure 1A) [138]. The betapolyomaviruses BK virus (BKV), JC virus (JCV), and simian virus 40 (SV40), encode two mature miRNAs originating from a single pre-miRNA found at the 3′ end, antisense to the large tumor antigen (LTAg) gene [135]. The miRNAs encoded by BKV (BKV-miR-B1-5p and 3p) and JCV (JCV-miR-J1-5p and 3p) have a very high sequence similarity, while the 5p and 3p arms of the SV40 miRNA (SV40-miR-S1) have only 50 and 75% sequence identity to the BKV and JCV miRNAs, respectively [139].

![Image](https://via.placeholder.com/150)

**Figure 1.** Betapolyomaviruses encode a miRNA in the LTAg region of the genome. (A) Genomic organization of the beta polyomaviruses BKV, JCV and SV40. The genome is divided into an early and late region encoded on opposite strands and separated by a non-coding control region (NCCR). The late strand of the genome encodes three capsid proteins (VP1-3) and two mature miRNAs originating from the same pre-miRNA located at the 3′ end and antisense to the large tumor antigen (LTAg) gene. The polyadenylation sites (pA) are involved in the early-to-late switch. (B) Perfect complementarity of the miRNA to the early viral LTAg mRNA results in direct cleavage and inhibition of LTAg expression to promote latency. The 3p arm of the miRNA directly downregulates expression of the stress-induced ligand ULBP3, contributing to immune evasion. The SV40-encoded miRNA 5p arm mimics hsa-miR-423 and is therefore suggested to contribute to cell transformation by downregulating the tumor suppressor ING-4.

The 5p BKV and JCV-encoded miRNAs are more abundantly expressed than the 3p miRNAs, and all PyV miRNAs show expression late during infection [139–141]. This observation is consistent
with PyV miRNAs being encoded on the late strand. Each miRNA is perfectly complementary to a region of the early viral LTAg mRNA and can therefore direct cleavage, resulting in inhibition of LTAg expression [135,139,142,143]. This downregulation of LTAg results in impairment of viral DNA replication and reduced recognition of PyV-infected cells by cytotoxic T lymphocytes [140]. Additionally, the 3p BKV and JCV miRNAs downregulate stress-induced cell surface markers, reducing NK and CD8\(^+\) T cell mediated killing of PyV-infected cells and contributing to immune evasion (Figure 1B) [144,145]. PyV-encoded miRNAs are therefore considered to play an important autoregulatory role in limiting viral replication, as well as in suppression of the immune response to infection [140]. These mechanisms may thus control the establishment of viral latency and/or persistence. However, recent data suggests that murine PyV miRNAs do not only play a role in limiting viral replication, but are also required to promote acute infection, suggesting that PyV miRNAs function in both persistent and acute phases of infection [146].

The virally encoded SV40-miR-S1-5p contains a seed region identical to that of the human miR-423-5p and is therefore suggested to negatively regulate the expression of several miR-423-5p target genes [147]. While little is known regarding the functions of these host proteins, the Inhibitor of Growth-4 (ING-4) gene is a tumor suppressor that regulates tumor growth and angiogenesis by directly binding and modulating p53, NF-κB, and HIF-1α activity [148–150]. Therefore, expression of SV40-miR-S1-5p may inhibit ING-4 expression, leading to tumor cell growth, invasion, angiogenesis, and activation of the AKT and ERK1/2 signaling pathways, similarly to miR-423-5p [151]. Reciprocally, human miR-423-5p might act as a functional ortholog of the viral miRNA, causing downregulation of LTAg, limiting viral replication [140]. A recent study also revealed a high level of similarity between SV40-miR-S1-3p and human miR-1266-3p, a miRNA known to promote breast and pancreatic cancer by targeting multiple negative regulators of the STAT3 and NF-κB signaling pathways, promoting cell survival and helping to confer resistance to chemotherapy [152–155]. However, whether this viral miRNA can serve as a functional ortholog remains to be shown.

Finally, increased expression of a cellular miRNA, miR-27a, was observed during SV40 infection. Overexpression of miR-27a in SV40-infected human bronchial epithelial cells results in dysregulation of cell cycle progression and contributes to malignant transformation [156,157]. Increased expression of miR-27a has also been shown to enhance expression of proinflammatory cytokines in TLR2/4-activated macrophages via targeting IL-10, and is often associated with adverse outcomes of malignancy [158,159]. Therefore, the potent tumorigenesis induced by SV40 infection might be due to both expression of virally encoded miRNAs, miR-S1-5p and -3p, as well as the induction of an oncogenic cellular miRNA, miR-27a. Thus, like herpesviruses, polyomavirus infection induces the expression of both cellular and viral miRNAs that promote viral latency and immune evasion, and these miRNAs may also underlie the potent cellular transformation and tumorigenesis induced by polyomaviruses.

4. Retroviruses

Retroviruses are ssRNA viruses that encode a reverse transcriptase and an integrase responsible for insertion of the proviral DNA into the host genome (Figure 2A) [160,161]. Human immunodeficiency virus 1 (HIV-1) is one of the most well-studied retroviruses due to its pathogenicity in human CD4\(^+\) T-cells. Interestingly, potential links between miRNA expression levels and permissiveness to HIV-1 infection have been reported. Resting memory CD4\(^+\) T-cells, which are less permissive to infection than activated CD4\(^+\) T-cells, display increased levels of five cellular miRNAs that target and inhibit several HIV-1 mRNAs [162]. Accordingly, these miRNAs are highly expressed in monocytes, a cell subset that is refractory to HIV-1 infection, but that progressively becomes more susceptible upon differentiation [163]. On the other hand, several cellular miRNAs have been shown to promote HIV-1 replication and their expression levels often correlate with permissiveness to HIV-1 infection (reviewed in [164]). One such example is miR-132, which is upregulated in activated CD4\(^+\) T-cells when compared to resting cells [165]. MiR-132 expression promotes viral replication in Jurkat T-cells, as well
as reactivation in latently infected cells. Results suggest that promotion of HIV-1 replication by miR-132 is mediated via the downregulation of a cellular transcriptional regulatory protein, MeCP2 [166,167]. However, reactivation of HIV-1 in latently infected cells was shown to be independent of MeCP2 downregulation, indicating that another mechanism is implicated in miR-132-mediated reactivation of HIV-1.

In addition to cellular miRNAs influencing HIV-1 infection, recent studies have reported the identification of HIV-1-derived miRNAs originating from coding and non-coding regions of the viral genome. Although there is controversy regarding whether these RNAs are authentic viral miRNAs based on criteria such as length and genome distribution (reviewed in [164]), several have been shown to functionally repress or promote HIV-1 replication (Figure 2A). For example, miR-N367, a negative regulatory factor (Nef)-derived miRNA, reduces HIV-1 transcription by inhibiting Nef gene expression and transcription of the long terminal repeat (LTR) region, while transactivation response element (TAR)-miR-5p and -3p both enhance infected cell survival by downregulating host genes implicated in apoptosis [168–171]. Finally, miR-H1 inhibits cellular miR-149 expression, which has been shown to downregulate viral protein R (Vpr) expression [172].

**Figure 2.** Genome organization of HIV-1 and strategies for suppression of RNA silencing. (A) The proviral DNA genome of HIV-1 encodes three structural genes (gag, pol and env) and several accessory genes (vif, vpr, vpu, tat, rev and nef) which regulate expression of viral proteins and play roles in immune evasion. The genome is flanked by long terminal repeats (LTRs), required for genome integration. Three functional miRNAs are encoded in the LTR region and Nef, which inhibit host and viral gene expression. The LTRs include the transactivation response (TAR) element stem-loop structure which can also be recognized by Dicer and TRBP and processed into TAR-miR-5p and -3p. (B) HIV-1 acts as a suppressor of RNA silencing. The Tat protein inhibits processing of pre-miRNAs by inhibiting Dicer activity. The Rev-response element (RRE) is a structured RNA element that resembles precursor miRNAs, able to compete with pre-miRNAs for TRBP binding.

Interestingly, HIV-1 has also been demonstrated to suppress the cellular RNA silencing pathway through multiple mechanisms (Figure 2B). The HIV-1 transactivator (Tat) protein was shown to act as a suppressor of RNA silencing through an RNA-dependent interaction with Dicer [173,174]. Although this interaction functionally abrogates Dicer activity, Tat binding appears to inhibit only a subset of miRNAs and leads to phenotypic changes in the central nervous system associated with HIV-1 neuropathogenesis [175]. Therefore, it is possible that Tat binds to specific precursor miRNAs in a sequence-dependent manner, inhibiting Dicer processing of this subset of miRNAs. Additionally, a structured RNA element of the HIV-1 genome, the Rev-response element (RRE), binds to the TRBP, a central component of the Dicer complex [176–178]. This interaction further inhibits the RNA silencing
pathway by competing with TRBP-bound RNAs [177]. Similarly to HIV-1, the primate foamy virus type 1 (PFV-1) encoded transactivator (Tas) also interferes with miRNA processing, and might function to overcome suppression of PFV-1 replication mediated by the cellular miRNA, miR-32 [179]. Thus, like the herpesviruses, retroviruses have been demonstrated to both encode viral miRNAs and modify cellular RNA silencing by inhibiting the processing of subsets of cellular miRNAs. This suppression of the cellular RNA silencing pathway may contribute to viral pathogenesis as well as cell permissibility.

5. Pestiviruses

Pestiviruses are small linear (+) ssRNA viruses of the Flaviviridae family. They commonly infect mammals, including cattle and pigs, and represent a serious threat to the food industry. Pestivirus infection can lead to diarrhea, respiratory symptoms, and reproductive dysfunctions, such as abortion [180]. In 2016, crosslinking immunoprecipitation (CLIP) studies of the Ago protein in the context of 15 different RNA virus infections revealed the functional binding of miR-17 and let-7 to the 3′ UTR of pestivirus genomic RNAs (Figure 3A,B) [181]. Canonical miR-17 and let-7 binding sites were identified in the 3′ UTR of the bovine viral diarrhea virus (BVDV) genome, specifically in the single-stranded region between SLI and SLII, and in the loop of SLII, respectively (Figure 3B) [181–183]. An additional non-canonical let-7 site, overlapping the miR-17 site, was supported by chimera-specific crosslinking-induced mutation site (CIMS) analysis [181]. This interaction involves extensive base pairing with the 3′ end of let-7 with only two nucleotides in the seed region (Figure 3B). Interestingly, these miR-17 and let-7 sites were both shown to be highly conserved among pestiviruses and the near-universal tropism of pestiviruses is concurrent with the ubiquitous expression of both these miRNAs across a range of tissues.

Contrasting with the canonical roles of miRNAs, binding of let-7 and miR-17 to the BVDV 3′ UTR was shown to increase both viral translation and RNA stability, with miR-17 playing a more predominant role in this regulation. Of note, Ago binding to the 3′ UTR of BVDV RNA was only observed at late time points (12–24 h post-infection) and not on replication-defective pol (-) mutant RNAs, which may suggest a role in the switch from translation to replication [181]. Mutational analyses of the non-canonical let-7 binding site revealed no effect on BVDV translation; thus, additional work is required to determine its role in the viral life cycle [181]. Binding of the miRNAs near the 3′ terminus might provide protection against 3′ exosome-mediated decay or suppress a long-range RNA–RNA interaction that is detrimental to internal ribosomal entry site (IRES) formation, similarly to models of miRNA regulation during hepatitis C virus (HCV) infection (discussed below) [184].

Interestingly, previous work suggests that the NFAR proteins bind to both the 5′ and 3′ UTRs of BVDV and help mediate genome circularization, a process promoting viral RNA translation [185]. Binding of miR-17 and let-7 at later time points during infection could therefore compete with NFAR proteins or induce conformational changes resulting in NFAR dissociation, followed by genome linearization and the switch to RNA replication. Binding of NFAR proteins to the BVDV genome involves SLI and SLIII of the 3′ UTR, with specific interactions mapped to the UGA box sequence elements [185]. Interestingly, the canonical let-7 site overlaps with the SLII UGA box element (Figure 3A,B). However, previous work demonstrated that while SLI is indispensable for pestivirus replication, deletion of either SLII or SLIII had no effect on viral translation, RNA replication, translation, packaging or particle production [186]. These results suggest that the canonical let-7 site (in SLII) is not essential for BVDV replication and that either SLII or SLIII is sufficient for recruitment of NFAR.

During viral replication, ~40% of the cellular miR-17 pool is sequestered by the BVDV genome, resulting in de-repression of many cellular miR-17 targets [187]. Conversely, let-7 sponging was <10%, likely due to the high abundance of this miRNA. However, the functional sequestration of miR-17 by BVDV did not appear to influence infection kinetics. Thus, it is unclear whether miRNA sponging by pestiviruses is simply a by-product of their dependence on a direct interaction with the viral genome, or if this mechanism also influences host gene expression in a manner that supports viral
replication. The miR-17/92 cluster is highly expressed in embryonic cells and, along with let-7, might be implicated in the high rate of abortion during BVDV infection due to its key role in embryonic development [188–190]. The miR-17/92 cluster is also involved in lymphocyte proliferation and its overexpression can lead to cancer and autoimmune disease [191]. Since pestiviruses primarily replicate in proliferating lymphocytes, miR-17 sponging in these cells could also result in lymphocyte apoptosis or decreased proliferation. Therefore, pestivirus-induced miRNA sponging could be a mechanism of immune evasion. On the other hand, both lymphopenia and BVDV tropism could simply be a by-product of the viral dependency on miR-17, as this miRNA is abundantly expressed in proliferating lymphocytes [192]. Additional putative miRNA binding sites were also identified by Ago CLIP across the BVDV ORF, including a let-7 site in the core coding region [181]. However, the read depth of the peaks across the ORF constituted only 3–4% of the reads, calling into question the relative importance of these potential additional interactions. Thus, taken together, let-7 and miR-17 binding accounts for >50% of the miRNA binding on the BVDV genome, and >80% of the binding to the 3′ UTR. Thus, let-7 and miR-17 are important regulators of viral translation and RNA stability in pestivirus infection, and further research will help to reveal their precise mechanism(s) of regulation.

**Figure 3.** Genome organization and miRNA binding sites in the BVDV and HCV genomes. The coding regions of BVDV and HCV are flanked by 5′ and 3′ untranslated regions (UTRs) characterized by specific stem-loop (SL) structures. (A) The BVDV genome includes UGA box sequence elements (boxed), a single-stranded (ss) RNA region, let-7 (blue) and miR-17 (green) binding sites. (B) Model of the binding interactions between the BVDV 3′ UTR and miR-17 and let-7. (C) The HCV genome contains two miR-122 binding sites (green) and an IRES element, which includes SLII-IV in the 5′ UTR. The 3′ UTR includes a hypervariable region (HV), a polyU/UC tract of variable length and a highly conserved 3′ X-tail, comprised of SL1-3. MiR-122 binds to two tandem sites in the 5′ UTRs of (D) HCV and (E) GBV-B. The nucleotides binding to the miRNA seed regions are underlined.

### 6. Hepaciviruses

The **hepacivirus** genus constitutes a group of hepatotropic, positive-sense, single-stranded RNA viruses of the **Flaviviridae** family that have been demonstrated to have a unique interaction with a liver-specific miRNA, miR-122. MiR-122 accounts for up to 72% of all the miRNAs found in the liver, with approximately 66,000 copies per cell, and it is highly conserved across vertebrates [193–195]. Although its normal role is in the regulation of cholesterol and fatty acid metabolism, it interacts with the 5′ UTR of several hepaciviruses and this interaction promotes viral RNA accumulation [196].

---

**Viruses 2018, 10, 440**

12 of 26
6.1. The Role of miR-122 in the Hepatitis C Virus (HCV) Life Cycle

Human miR-122 has been demonstrated to promote viral RNA accumulation in both HCV-infected cells, and in the livers of infected patients, independently of its effects on cholesterol and lipid metabolism [197–199]. Moreover, HCV RNA accumulation is dependent upon the miRNA biogenesis pathway, presumably due to this reliance on miR-122, as the depletion of any of the four human Ago proteins, or other key players involved in miRNA biogenesis, leads to a significant decrease in viral RNA abundance in cell culture [200,201]. MiR-122 binds to two “tandem” seed match sequences in the 5′ UTR of the HCV genome, and has additional interactions with nucleotides 1-3 and 29-31, creating a 3′ overhang at the 5′ terminus of the viral genome (Figure 3C,D) [202,203]. Stepwise mutational analyses suggest that both miR-122 binding sites are important for viral RNA accumulation and that they cooperatively support viral RNA accumulation. These analyses also indicated that nucleotides in the bulge and 3′ tail of miR-122 are important for maintaining HCV RNA abundance as mutation, truncation, or exchange of the 3′ terminal ribonucleotides of miR-122 for deoxynucleotides reduces HCV RNA accumulation. However, these nucleotides were not required for canonical miRNA activities (i.e., target cleavage and translational inhibition) [202]. These results suggest that sequences in the 3′ tail of miR-122 may mediate important interactions with viral or cellular factors involved in HCV RNA accumulation. Although the precise mechanism(s) of miR-122-mediated viral RNA accumulation have remained elusive, recent studies have suggested two major mechanisms in the viral life cycle: protection of the viral genome from 5′ decay and modification of the viral RNA structure in a manner that promotes HCV IRES-mediated translation (discussed in more detail below).

6.2. MiR-122 Protects the HCV Genome from Cellular Pyrophosphatase and 5′ Exonuclease Activities

The finding that miR-122 binds to the 5′ terminus of the viral RNA creating a 3′ overhang suggested a role for miR-122 in protection from nucleases or recognition by cellular sensors of RNA [202]. Recent work suggests that miR-122 binding to the 5′ terminus of the HCV genome protects the viral 5′ triphosphate moiety from recognition by cellular pyrophosphatasases DOM3Z and DUSP11, and subsequent 5′ exonuclease-mediated decay [204]. Knockdown of both these cellular pyrophosphatasases was shown to significantly increase viral RNA accumulation in cell culture and was also demonstrated to stabilize the HCV genome in the absence of miR-122. Moreover, knockdown of the pyrophosphatasases in combination with the 5′ exonuclease (Xrn1) further increased viral RNA accumulation [204]. These observations were further confirmed by enhanced HCV replication and decreased miR-122 dependency in DUSP11 knockout cells [205]. Taken together, these results support a model whereby in the absence of the miR-122, DOM3Z and/or DUSP11 can mediate conversion of the 5′ triphosphate of the HCV genome to a monophosphate. This renders the viral genome susceptible to decay mediated by the cellular 5′ exonucleases, Xrn1 and/or Xrn2 [206–210]. Thus, miR-122 promotes HCV RNA stability by protecting the viral RNA from both pyrophosphatase activity and subsequent 5′ exonuclease-mediated decay.

6.3. MiR-122 Binding to the 5′ UTR Alters the Structure of the HCV Genome

Recent studies have also revealed that miR-122 binding to the HCV genome alters the structure of the 5′ UTR in a manner that promotes viral RNA translation. Schult et al. demonstrated that miR-122 binding to the viral 5′ UTR contributes to the folding of a functional IRES in an RNA chaperone-like manner [184]. In silico structure predictions, as well as selective 2′ hydroxyl acylation analyzed by primer extension (SHAPE) and nuclear magnetic resonance (NMR) analyses of the 5′ UTR in the absence of miR-122, identified an alternative structure for the SLII region that is more energetically favorable (SLIIalt). This structure includes parts of SLII, preventing formation of a functional IRES element and impairing viral translation. Binding of miR-122 prevents the formation of SLIIalt, thereby favoring SLII formation which drives the assembly of the pre-initiation complex. Indeed, polysome-profiling indicates more efficient association of the viral RNA with the 80S ribosome...
on either wild-type HCV RNA in the presence of miR-122, or on HCV mutants which favor SLII formation in the absence of miR-122 [211]. These observations are supported by previous studies, where in vitro characterization of a miR-122-sensitive double-helical switch element in the 5′ region of HCV genome indicated that a structural transition in HCV RNA conformation might impact viral translation [212]. The proposed model suggests that the IRES resides within a locked conformation, which switches to an open conformation upon interactions with miR-122. Moreover, the eukaryotic translation initiation factor 4AII (eIF4AII), which is normally implicated in miRNA-mediated mRNA translational repression, was recently shown to interact with the HCV genome in a miR-122-dependent manner and to contribute to IRES-mediated translation [213,214]. Taken together, these results support the model whereby miR-122 binding to the 5′ UTR promotes SLII formation, leading to 80S ribosome assembly and translation initiation. MiR-122 dependency can also be further explained by the dual function of the 5′ terminal sequences in the negative strand, which represents the positive-strand promoter region. Indeed, the 3′ end of the negative strand forms an extensive set of stem-loop structures, similar to that of SLIIalt, which are crucial for viral RNA replication [215,216]. Finally, several mutations have been identified in the HCV 5′ UTR that confer low levels of viral RNA replication in a miR-122-independent manner, and in support of this model, these mutations would be predicted to favor formation of SLII, even in the absence of miR-122 [217–219].

6.4. Dysregulation of miR-122 May Contribute to Viral Pathogenesis

Like the pestiviruses, a genome-wide miR-122 binding profile revealed functional sequestration of miR-122 during HCV infection [220]. This “sponge” effect results in de-repression of canonical miR-122 targets and deregulation of collagen production, enhanced cell proliferation and survival, and activation of hepatic stellate cells, resulting in a proinflammatory response [221–223]. Furthermore, miR-122 has been demonstrated to be a tumor suppressor [224,225]. Thus, in addition to promoting HCV RNA accumulation, miR-122 sequestration by the HCV genome may promote cell transformation and development of hepatocellular carcinoma.

6.5. MiR-122 Binding May Be a Common Strategy for Viral RNA Accumulation among Hepaciviruses

In addition to binding to the HCV genome, miR-122 binding sites have been found in the 5′ UTR of several other hepaciviruses, including GB virus B (GBV-B) (Figure 3E), non-primate hepacivirus (NPHV), several rodent hepaciviruses (RHV), and bovine hepacivirus (BovHepV) [226–229]. Although culture systems are not available for many of these novel hepaciviruses, the presence of conserved miR-122 binding sites provides hints with regard to their likely liver tissue tropism, and may suggest a conserved mechanism for viral RNA accumulation across this genus. Accordingly, both GBV-B and NPHV have been shown to be miR-122 responsive [226]. These results suggest that miR-122 binding may be a conserved mechanism for viral RNA accumulation in hepaciviruses and might help them to exploit the tolerogenic liver environment [219,230].

7. Conclusions

Since miRNAs are involved in all facets of cellular activities, they have major influences on viral infections and can both restrict or promote viral replication and pathogenesis. Accordingly, several viral families have evolved multiple mechanisms to take advantage of miRNAs and/or the miRNA pathway. DNA viruses, namely the herpesviruses and polyomaviruses, encode their own miRNA(s) that along with cellular miRNAs play important roles in latency maintenance, immune evasion, and tumorigenesis. Retroviruses have also been shown to encode miRNAs that modulate viral replication and pathogenesis, but are also known to encode proteins that modulate cellular miRNA processing, which is linked to viral pathogenesis and cell permissivity. In contrast, RNA viruses do not typically encode their own miRNAs; however, the pestiviruses and hepaciviruses bind to specific host miRNAs to promote viral translation, replication and/or genome stability. Of note, the ability of HCV and BVDV to use miRNAs to stabilize their genome by binding to the 5′ or 3′ UTRs, respectively, suggests that
these interactions may have evolved independently [231]. Overall, these results highlight the different mechanisms by which miRNAs can influence DNA and RNA virus infection and be exploited by viruses to promote viral infection and pathogenesis. Studying these diverse interactions has provided unique insights into the canonical and non-canonical roles of miRNAs in the regulation of host and viral gene expression.

Author Contributions: A.B. drafted the manuscript, A.B. and S.M.S. revised and edited the final manuscript. All authors have approved the manuscript submission.

Acknowledgments: This work was supported by start-up funds from McGill University as well as grants from the Canadian Institutes of Health Research [MOP-136915] to S.M.S. A.B. is supported by the Canadian Network on Hepatitis C (CanHepC) training program, as well as a doctoral fellowship from Fonds de la Recherche en Santé du Québec (FRSQ). In addition, this research was undertaken, in part, thanks to funding from the Canada Research Chairs program.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Lee, R.C.; Feinbaum, R.L.; Ambros, V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993, 75, 843–854. [CrossRef] [PubMed]
2. Kozomara, A.; Griffiths-Jones, S. miRNA: Annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res. 2014, 42. [CrossRef] [PubMed]
3. Rodriguez, A.; Griffiths-Jones, S.; Ashurst, J.L.; Bradley, A. Identification of mammalian microRNA host genes and transcription units. Genome Res. 2004, 14, 1902–1910. [CrossRef] [PubMed]
4. Lee, Y.; Kim, M.; Han, J.; Yeom, K.H.; Lee, S.; Baek, S.H.; Kim, V.N. MicroRNA genes are transcribed by RNA polymerase II. EMBO J. 2004, 23, 4051–4060. [CrossRef] [PubMed]
5. Lee, Y.; Ahn, C.; Han, J.; Choi, H.; Kim, J.; Yim, J.; Lee, J.; Provost, P.; Radmark, O.; Kim, S.; et al. The nuclear RNase III Drosha initiates microRNA processing. Nature 2003, 425, 415–419. [CrossRef] [PubMed]
6. Bernstein, E.; Caudy, A.A.; Hammond, S.M.; Hannon, G. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 2001, 409, 363–366. [CrossRef] [PubMed]
7. Knight, S.W.; Bass, B.L. A role for the RNase III enzyme DCR-1 in RNA interference and germ line development in Caenorhabditis elegans. Science 2001, 293, 2269–2271. [CrossRef] [PubMed]
8. Hutvagner, G.; McLachlan, J.; Pasquinelli, A.E.; Balint, E.; Tuschl, T.; Zamore, P.D. A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA. Science 2001, 293, 834–838. [CrossRef] [PubMed]
9. Lee, H.Y.; Zhou, K.; Smith, A.M.; Noland, C.L.; Doudna, J.A. New class of microRNA targets containing simultaneous 5′-UTR and 3′-UTR interaction sites. Genome Res. 2009, 19, 1175–1183. [CrossRef] [PubMed]
10. Mourelatos, Z.; Dostie, J.; Paushkin, S.; Sharma, A.; Charroux, B.; Abel, L.; Rappsilber, J.; Mann, M.; Dreyfuss, G. miRNPs: A novel class of ribonucleoproteins containing numerous microRNAs. Genes Dev. 2002, 16, 720–728. [CrossRef] [PubMed]
11. Lee, I.; Ajay, S.S.; Yook, J.I.; Kim, H.S.; Hong, S.H.; Kim, N.H.; Dhanasekaran, S.M.; Chinnaiyan, A.M.; Athey, B.D. New class of microRNA targets containing simultaneous 5′-UTR and 3′-UTR interaction sites. Genome Res. 2009, 19, 1175–1183. [CrossRef] [PubMed]
12. Fang, Z.; Rajewsky, N. The impact of miRNA target sites in coding sequences and in 3′ UTRs. PLoS ONE 2011, 6, e18067. [CrossRef] [PubMed]
13. Haussler, J.; Syed, A.P.; Bielen, B.; Zavolan, M. Analysis of CDS-located miRNA target sites suggests that they can effectively inhibit translation. Genome Res. 2013, 23, 604–615. [CrossRef] [PubMed]
14. Meijer, H.A.; Smith, E.M.; Bushell, M. Regulation of miRNA strand selection: Follow the leader? Biochem. Soc. Trans. 2014, 42, 1135–1140. [CrossRef] [PubMed]
15. Hu, H.Y.; Yan, Z.; Xu, Y.; Hu, H.; Menzel, C.; Zhou, Y.H.; Chen, W.; Khaitovich, P. Sequence features associated with microRNA strand selection in humans and flies. BMC Genom. 2009, 10, 413. [CrossRef] [PubMed]
16. Lewis, B.P.; Shih, I.H.; Jones-Rhoades, M.W.; Bartel, D.P.; Burge, C.B. Prediction of mammalian microRNA targets. Cell 2003, 115, 787–798. [CrossRef]
17. Shin, C.; Nam, J.W.; Farh, K.K.; Chiang, H.R.; Shkumatava, A.; Bartel, D.P. Expanding the microRNA targeting code: Functional sites with centered pairing. *Mol. Cell* **2010**, *38*, 789–802. [CrossRef] [PubMed]

18. Bartel, D.P. MicroRNAs: Genomics, biogenesis, mechanism, and function. *Cell* **2004**, *116*, 281–297. [CrossRef]

19. Brennecke, J.; Stark, A.; Russell, R.B.; Cohen, S.M. Principles of microRNA-target recognition. *PLoS Biol.* **2005**, 3, e85. [CrossRef] [PubMed]

20. Axtell, M.J.; Westholm, J.O.; Lai, E.C. Vive la difference: Biogenesis and evolution of microRNAs in plants and animals. *Genome Biol.* **2011**, 12, 221. [CrossRef] [PubMed]

21. Rajewsky, N. microRNA target predictions in animals. *Nat. Genet.* **2006**, *38*, S8–S13. [CrossRef] [PubMed]

22. Rajewsky, N.; Socci, N.D. Computational identification of microRNA targets. *Dev. Biol.* **2004**, *267*, 529–535. [CrossRef] [PubMed]

23. Friedman, R.C.; Farh, K.K.; Burge, C.B.; Bartel, D.P. Most mammalian mRNAs are conserved targets of microRNAs. *Genome Res.* **2009**, 19, 92–105. [CrossRef] [PubMed]

24. Vienberg, S.; Geiger, J.; Madsen, S.; Dalgaard, L.T. MicroRNAs in metabolism. *Acta Physiol.* **2017**, *219*, 346–361. [CrossRef] [PubMed]

25. Landgraf, P.; Rusu, M.; Sheridan, R.; Sewer, A.; Iovino, N.; Aravin, A.; Pfeffer, S.; Rice, A.; Kamphorst, A.O.; Landthaler, M.; et al. A mammalian microRNA expression atlas based on small RNA library sequencing. *Cell* **2007**, 129, 1401–1414. [CrossRef] [PubMed]

26. Alberti, C.; Cochella, L. A framework for understanding the roles of miRNAs in animal development. *Development* **2017**, *144*, 2548–2559. [CrossRef] [PubMed]

27. O’Connell, R.M.; Rao, D.S.; Chaudhuri, A.A.; Baltimore, D. Physiological and pathological roles for microRNAs in the immune system. *Nat. Rev. Immunol.* **2010**, *10*, 111–122. [CrossRef] [PubMed]

28. Boehmer, P.E.; Nimonkar, A.V. Herpes virus replication. *IUBMB Life* **2003**, *55*, 13–22. [CrossRef] [PubMed]

29. Davison, A.J. Overview of classification. In *Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis*; Arvin, A., Campadelli-Fiume, G., Mocarski, E., Moore, P.S., Roizman, B., Whitley, R., Yamanishi, K., Eds.; Cambridge University Press: Cambridge, UK, 2007.

30. Cullen, B.R. Herpesvirus microRNAs: Phenotypes and functions. *Curr. Opin. Virol.* **2011**, *1*, 211–215. [CrossRef] [PubMed]

31. Piedade, D.; Azevedo-Pereira, J.M. The Role of microRNAs in the Pathogenesis of Herpesvirus Infection. *Viruses* **2016**, *8*, 156. [CrossRef] [PubMed]

32. Pinnoji, R.C.; Bedadala, G.R.; George, B.; Holland, T.C.; Hill, J.M.; Hsia, S.C. Repressor element-1 silencing transcription factor/neuronal restrictive silencer factor (REST/NRSF) can regulate HSV-1 immediate-early protein translation promotes viral latency. *J. Virol.* **2007**, *74*, 4516–4523. [CrossRef] [PubMed]

33. Wang, X.; Diao, C.; Yang, X.; Yang, Z.; Liu, M.; Li, X.; Tang, H. ICP4-induced miR-101 attenuates HSV-1 replication. *Sci. Rep.* **2016**, *6*, 2305. [CrossRef] [PubMed]

34. Zheng, S.Q.; Li, Y.X.; Zhang, Y.; Li, X.; Tang, H. MiR-101 regulates HSV-1 replication by targeting ATP5B. *Antivir. Res.* **2011**, *89*, 219–226. [CrossRef] [PubMed]

35. Dasgupta, A.; Wilson, D.W. ATP depletion blocks herpes simplex virus DNA packaging and capsid maturation. *J. Virol.* **1999**, *73*, 2006–2015. [PubMed]

36. Pan, D.; Flores, O.; Umbach, J.L.; Pesola, J.M.; Bentley, P.; Rosato, P.C.; Leib, D.A.; Cullen, B.R.; Coen, D.M. A neuron-specific host microRNA targets herpes simplex virus-1 ICP0 expression and promotes latency. *Cell Host Microbe* **2014**, *15*, 446–456. [CrossRef] [PubMed]

37. Varani, S.; Landini, M.P. Cytomegalovirus-induced immunopathology and its clinical consequences. *Herpesviridae* **2011**, *2*, 6. [CrossRef] [PubMed]

38. Brit, W. Manifestations of human cytomegalovirus infection: Proposed mechanisms of acute and chronic disease. *Curr. Top. Microbiol. Immunol.* **2008**, *325*, 417–470. [PubMed]

39. O’Connor, C.M.; Vanieck, J.; Murphy, E.A. Host microRNA regulation of human cytomegalovirus immediate early protein translation promotes viral latency. *J. Virol.* **2014**, *88*, 5524–5532. [CrossRef] [PubMed]

40. Thorley-Lawson, D.A.; Hawkins, J.B.; Tracy, S.I.; Shapiro, M. The pathogenesis of Epstein-Barr virus persistent infection. *Curr. Opin. Virol.* **2013**, *3*, 227–232. [CrossRef] [PubMed]

41. Ellis-Connell, A.L.; Lempridee, T.; Xu, I.; Mertz, J.E. Cellular microRNAs 200b and 429 regulate the Epstein-Barr virus switch between latency and lytic replication. *J. Virol.* **2010**, *84*, 10329–10343. [CrossRef] [PubMed]
42. Ellis, A.L.; Wang, Z.; Yu, X.; Mertz, J.E. Either ZEB1 or ZEB2/SIP1 can play a central role in regulating the Epstein-Barr virus latent-lytic switch in a cell-type-specific manner. *J. Virol.* 2010, 84, 6139–6152. [CrossRef] [PubMed]

43. Mansouri, S.; Pan, Q.; Blencowe, B.J.; Claycomb, J.M.; Frappier, L. Epstein-Barr virus EBNA1 protein regulates viral latency through effects on let-7 microRNA and dicer. *J. Virol.* 2014, 88, 11166–11177. [CrossRef] [PubMed]

44. Yates, J.L.; Warren, N.; Sugden, B. Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. *Nature* 1985, 313, 812–815. [CrossRef] [PubMed]

45. Frappier, L. EBNA1 and host factors in Epstein-Barr virus latent DNA replication. *Curr. Opin. Virol.* 2012, 2, 733–739. [CrossRef] [PubMed]

46. Yan, Q.; Li, W.; Tang, Q.; Yao, S.; Lu, Z.; Feng, N.; Ma, X.; Bai, Z.; Zeng, Y.; Qin, D.; et al. Cellular microRNAs 498 and 320d regulate herpes simplex virus 1 induction of Kaposi’s sarcoma-associated herpesvirus lytic replication by targeting RTA. *PLoS ONE* 2013, 8, e55832. [CrossRef] [PubMed]

47. Yan, Q.; Ma, X.; Shen, C.; Cao, X.; Feng, N.; Qin, D.; Zeng, Y.; Zhu, J.; Gao, S.J.; Lu, C. Inhibition of Kaposi’s sarcoma-associated herpesvirus lytic replication by HIV-1 Nef and cellular microRNA hsa-miR-1258. *J. Virol.* 2014, 88, 4987–5000. [CrossRef] [PubMed]

48. Kobayashi, K.; Suemasa, F.; Sagara, H.; Nakamura, S.; Ino, Y.; Kobayashi, K.; Hiramatsu, H.; Haraguchi, T.; Kurokawa, K.; Todo, T.; et al. MiR-199a Inhibits Secondary Envelopment of Herpes Simplex Virus-1 Through the Downregulation of Cdc42-specific GTPase Activating Protein Localized in Golgi Apparatus. *Sci. Rep.* 2017, 7, 6650. [CrossRef] [PubMed]

49. Hill, J.M.; Zhao, Y.; Clement, C.; Neumann, D.M.; Lukiw, W.J. HSV-1 infection of human brain cells induces miRNA-146a and Alzheimer-type inflammatory signaling. *Neuroreport* 2009, 20, 1500–1505. [CrossRef] [PubMed]

50. Snowden, S.G.; Ebshiana, A.A.; Hye, A.; An, Y.; Pletnikova, O.; O’Brien, R.; Troncoso, J.; Legido-Quigley, C.; Thambisetty, M. Association between fatty acid metabolism in the brain and Alzheimer disease neuropathology and cognitive performance: A nontargeted metabolomic study. *PLoS Med.* 2017, 14, e1002266. [CrossRef] [PubMed]

51. Ru, J.; Sun, H.; Fan, H.; Wang, C.; Li, Y.; Liu, M.; Tang, H. MiR-23a facilitates the replication of HSV-1 through the suppression of interferon regulatory factor 1. *PLoS ONE* 2014, 9, e114021. [CrossRef] [PubMed]

52. Liu, X.; Ru, J.; Zhang, J.; Zhu, L.H.; Liu, M.; Li, X.; Tang, H. miR-23a targets interferon regulatory factor 1 and modulates cellular proliferation and paclitaxel-induced apoptosis in gastric adenocarcinoma cells. *PLoS ONE* 2013, 8, e64707. [CrossRef] [PubMed]

53. Zhang, Y.; Dai, J.; Tang, J.; Zhou, L.; Zhou, M. MicroRNA-649 promotes HSV-1 replication by directly targeting MALTI. *J. Med. Virol.* 2017, 89, 1069–1079. [CrossRef] [PubMed]

54. Yu, J.W.; Hoffman, S.; Beal, A.M.; Dykon, A.; Ringenberg, M.A.; Hughes, A.C.; Dare, L.; Anderson, A.D.; Finger, J.; Kasparcova, V.; et al. MALTI Protease Activity Is Required for Innate and Adaptive Immune Responses. *PLoS ONE* 2015, 10, e0127083. [CrossRef] [PubMed]

55. Lagos, D.; Pollara, G.; Henderson, S.; Gratrix, F.; Fabani, M.; Milne, R.S.; Gotch, F.; Boshoff, C. miR-132 regulates antiviral innate immunity through suppression of the p300 transcriptional co-activator. *Nat. Cell Biol.* 2010, 12, 513–519. [CrossRef] [PubMed]

56. Fu, Y.R.; Liu, X.J.; Li, X.J.; Shen, Z.Z.; Yang, B.; Wu, C.C.; Li, J.F.; Miao, L.F.; Ye, H.Q.; Qiao, G.H.; et al. MicroRNA miR-21 attenuates human cytomegalovirus replication in neural cells by targeting Cdc25a. *J. Virol.* 2015, 89, 1070–1082. [CrossRef] [PubMed]

57. Wang, L.; Yang, L.; Liao, S.; Liu, W.; Dai, G.; Wu, G.; Chen, L. Hsa-miR-27b is up-regulated in cytomegalovirus-infected human glioma cells, targets engrailed-2 and inhibits its expression. *Exp. Biol. Med.* 2017, 1. [CrossRef] [PubMed]

58. Cramer, E.M.; Shao, Y.; Wang, Y.; Yuan, Y. miR-190 is upregulated in Epstein-Barr Virus type I latency and modulates cellular mRNAs involved in cell survival and viral reactivation. *Virology* 2014, 464–465, 184–195. [CrossRef] [PubMed]

59. Imig, J.; Motsch, N.; Zhu, J.Y.; Barth, S.; Okoniewski, M.; Reineke, T.; Tinguely, M.; Faggioni, A.; Trivedi, P.; Meister, G.; et al. microRNA profiling in Epstein-Barr virus-associated B-cell lymphoma. *Nucleic Acids Res.* 2011, 39, 1880–1893. [CrossRef] [PubMed]
60. Onnis, A.; Navari, M.; Antonicelli, G.; Morettini, F.; Mannucci, S.; De Falco, G.; Vigorito, E.; Leoncini, L. Epstein-Barr nuclear antigen 1 induces expression of the cellular microRNA hsa-miR-127 and impairing B-cell differentiation in EBV-infected memory B cells. New insights into the pathogenesis of Burkitt lymphoma. *Blood Cancer J.* 2012, 2, e84. [CrossRef] [PubMed]

61. Tsai, Y.H.; Wu, M.F.; Wu, Y.H.; Chang, S.J.; Lin, S.F.; Sharp, T.V.; Wang, H.W. The M type K15 protein of Kaposi’s sarcoma-associated herpesvirus regulates microRNA expression via its SH2-binding motif to induce cell migration and invasion. *J. Virol.* 2009, 83, 622–632. [CrossRef] [PubMed]

62. Meng, F.; Henson, R.; Webbe-Janek, H.; Ghoshal, K.; Jacob, S.T.; Patel, T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. *Gastroenterology* 2007, 133, 647–658. [CrossRef] [PubMed]

63. Asangani, I.A.; Rasheed, S.A.; Nikolova, D.A.; Leupold, J.H.; Colburn, N.H.; Post, S.; Allgayer, H. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. *Oncogene* 2008, 27, 2128–2136. [CrossRef] [PubMed]

64. Wu, Y.H.; Hu, T.F.; Chen, Y.C.; Tsai, Y.N.; Tsai, Y.H.; Cheng, C.C.; Wang, H.W. The manipulation of miRNA-gene regulatory networks by KSHV induces endothelial cell motility. *Blood* 2011, 118, 2896–2905. [CrossRef] [PubMed]

65. Punj, V.; Matta, H.; Schemus, S.; Tamewitz, A.; Anyang, B.; Chaudhary, P.M. Kaposi’s sarcoma-associated herpesvirus-encoded viral FLICE inhibitory protein (vFLIP) K13 suppresses CXCR4 expression by upregulating miR-146a. *Oncogene* 2010, 29, 1835–1844. [CrossRef] [PubMed]

66. Redpath, S.; Angulo, A.; Gascoigne, N.R.; Ghazal, P. Immune checkpoints in viral latency. *Annu. Rev. Microbiol.* 2001, 55, 531–560. [CrossRef] [PubMed]

67. Leucci, E.; Onnis, A.; Cocco, M.; De Falco, G.; Imperatore, F.; Giuseppina, A.; Costanzo, V.; Cerino, G.; Mannucci, S.; Cantisani, R.; et al. B-cell differentiation in EBV-positive Burkitt lymphoma is impaired at posttranscriptional level by miRNA-altered expression. *Int. J. Cancer* 2010, 126, 1316–1326. [CrossRef] [PubMed]
78. Kincaid, R.P.; Sullivan, C.S. Virus-encoded microRNAs: An overview and a look to the future. *PLoS Pathog.* 2012, 8, e1003018. [CrossRef] [PubMed]

79. Kim, H.; Izasa, H.; Kamehiro, Y.; Fekadu, S.; Yoshiyama, H. Herpesviral microRNAs in Cellular Metabolism and Immune Responses. *Front. Microbiol.* 2017, 8, 1318. [CrossRef] [PubMed]

80. Cardin, S.; Borchert, G.M. Viral MicroRNAs, Host MicroRNAs Regulating Viruses, and Bacterial MicroRNA-Like RNAs. In *Bioinformatics in MicroRNA Research*; Al, H.J.E., Ed.; Humana Press: New York, NY, USA, 2017; pp. 39–56.

81. Markus, A.; Golani, L.; Ojha, N.K.; Borodiansky-Shteinberg, T.; Kinchington, P.R.; Goldstein, R.S. Varicella-Zoster Virus Expresses Multiple Small Noncoding RNAs. *J. Virol.* 2017, 91. [CrossRef] [PubMed]

82. Wu, W.; Guo, Z.; Zhang, X.; Guo, L.; Liu, L.; Liao, Y.; Wang, J.; Wang, L.; Li, Q. A microRNA encoded by HSV-1 inhibits a cellular transcriptional repressor of viral immediate early and early genes. *Sci. China Life Sci.* 2013, 56, 373–383. [CrossRef] [PubMed]

83. Enk, J.; Levi, A.; Weisblum, Y.; Yamin, R.; Charpak-Amikam, Y.; Wolf, D.G.; Mandelboim, O. HSV1 MicroRNA Modulation of GPI Anchoring and Downstream Immune Evasion. *Cell Rep.* 2016, 17, 949–956. [CrossRef] [PubMed]

84. Zheng, K.; Liu, Q.; Wang, S.; Ren, Z.; Kitazato, K.; Yang, D.; Wang, Y. HSV-1-encoded microRNA miR-H1 targets Ubr1 to promote accumulation of neurodegeneration-associated protein. *Virus Genes* 2018, 54, 343–350. [CrossRef] [PubMed]

85. Chen, M.; Gerlier, D. Viral hijacking of cellular ubiquitination pathways as an anti-innate immunity strategy. *Viral Immunol.* 2006, 19, 349–362. [CrossRef] [PubMed]

86. Stern-Ginossar, N.; Elefant, N.; Zimmermann, A.; Wolf, D.G.; Saleh, N.; Biton, M.; Horwitz, E.; Prokocimer, Z.; Prichard, M.; Hahn, G.; et al. Host immune system gene targeting by a viral miRNA. *Science* 2007, 317, 376–381. [CrossRef] [PubMed]

87. Nachmani, D.; Lankry, D.; Wolf, D.G.; Mandelboim, O. The human cytomegalovirus microRNA miR-UL112 acts synergistically with a cellular microRNA to escape immune elimination. *Nat. Immunol.* 2010, 11, 806–813. [CrossRef] [PubMed]

88. Nachmani, D.; Stern-Ginossar, N.; Sarid, R.; Mandelboim, O. Diverse herpesvirus microRNAs target the stress-induced immune ligand MICB to escape recognition by natural killer cells. *Cell Host Microbe* 2009, 5, 376–385. [CrossRef] [PubMed]

89. Esteso, G.; Luzon, E.; Sarmiento, E.; Gomez-Caro, R.; Steinle, A.; Murphy, G.; Carbone, J.; Vales-Gomez, M.; Reyburn, H.T. Altered microRNA expression after infection with human cytomegalovirus leads to TIMP3 downregulation and increased shedding of metalloprotease substrates, including MICA. *J. Immunol.* 2014, 193, 1344–1352. [CrossRef] [PubMed]

90. Kim, Y.; Lee, S.; Kim, S.; Kim, D.; Ahn, J.H.; Ahn, K. Human cytomegalovirus clinical strain-specific microRNA miR-UL148D targets the human chemokine RANTES during infection. *PLoS Pathog.* 2012, 8, e1002577. [CrossRef] [PubMed]

91. Maghazachi, A.A.; Al-Aoukaty, A.; Schall, T.J. CC chemokines induce the generation of killer cells from CD56+ cells. *Eur. J. Immunol.* 1996, 26, 315–319. [CrossRef] [PubMed]

92. Hook, L.M.; Grey, F.; Grabski, R.; Tirabassi, R.; Doyle, T.; Hancock, M.; Landais, I.; Jing, S.; McWeeney, S.; Britt, W.; et al. Cytomegalovirus miRNAs target secretory pathway genes to facilitate formation of the virion assembly compartment and reduce cytokine secretion. *Cell Host Microbe* 2014, 15, 363–373. [CrossRef] [PubMed]

93. Albanese, M.; Tagawa, T.; Buschle, A.; Hammerschmidt, W. MicroRNAs of Epstein-Barr Virus Control Innate and Adaptive Antiviral Immunity. *J. Virol.* 2017, 91. [CrossRef] [PubMed]

94. Wang, M.; Yu, F.; Wu, W.; Wang, Y.; Ding, H.; Qian, L. Epstein-Barr virus-encoded microRNAs as regulators in host immune responses. *Int. J. Biol. Sci.* 2018, 14, 565–576. [CrossRef] [PubMed]

95. Iizasa, H.; Wulff, B.E.; Alla, N.R.; Maragkakis, M.; Megraw, M.; Hatzigeorgiou, A.; Ivakiri, D.; Takada, K.; Wiedmer, A.; Showe, L.; et al. Editing of Epstein-Barr virus-encoded BART6 microRNAs controls their dicer targeting and consequently affects viral latency. *J. Biol. Chem.* 2010, 285, 33358–33370. [CrossRef] [PubMed]

96. Xia, T.; O’Hara, A.; Araujo, I.; Barreto, J.; Carvalho, E.; Sapucaia, J.B.; Ramos, J.C.; Luz, E.; Pedroso, C.; Manrique, M.; et al. EBV microRNAs in primary lymphomas and targeting of CXCL-11 by ebv-mir-BHRF1-3. *Cancer Res.* 2008, 68, 1436–1442. [CrossRef] [PubMed]
Viruses 2018, 10, 440

97. Lu, Y.; Qin, Z.; Wang, J.; Zheng, X.; Lu, J.; Zhang, X.; Wei, L.; Peng, Q.; Zheng, Y.; Ou, C.; et al. Epstein-Barr Virus miR-BART6-3p Inhibits the RIG-I Pathway. *J. Innate Immun.* 2017, 9, 574–586. [CrossRef] [PubMed]

98. Choy, E.Y.; Siu, K.L.; Kok, K.H.; Lung, R.W.; Tsang, C.M.; To, K.F.; Kwong, D.L.; Tsao, S.W.; Jin, D.Y. An Epstein-Barr virus-encoded microRNA targets PUMA to promote host cell survival. *J. Exp. Med.* 2008, 205, 2551–2560. [CrossRef] [PubMed]

99. Navari, M.; Etebari, M.; Ibrahimi, M.; Leoncini, L.; Piccaluga, P. Pathobiologic Roles of Epstein-Barr Virus-Encoded MicroRNAs in Human Lymphomas. *Int. J. Mol. Sci.* 2018, 19, 1168. [CrossRef] [PubMed]

100. Hislop, A.D.; Taylor, G.S.; Sauce, D.; Richardson, A.B. Cellular responses to viral infection in humans: Lessons from Epstein-Barr virus. *Annu. Rev. Immunol.* 2007, 25, 587–617. [CrossRef] [PubMed]

101. Pagano, J.S.; Blaser, M.; Buendia, M.A.; Damania, B.; Khalili, K.; Raab-Traub, N.; Roizman, B. Infectious agents and cancer: Criteria for a causal relation. *Semin. Cancer Biol.* 2004, 14, 453–471. [CrossRef] [PubMed]

102. Happel, C.; Ramalingam, D.; Ziegelbauer, J.M. Virus-Mediated Alterations in miRNA Factors and Degradation of Viral miRNAs by MCPIP1. *PLoS Biol.* 2016, 14, e2000998. [CrossRef] [PubMed]

103. Mizgalska, D.; Wegrzyn, P.; Murzyn, K.; Kasza, A.; Koj, A.; Jura, J.; Jarzab, B.; Jura, J. Interleukin-1-inducible MCPIP protein has structural and functional properties of RNase and participates in degradation of IL-1beta mRNA. *FEBS J.* 2009, 276, 7386–7399. [CrossRef] [PubMed]

104. Matsushita, K.; Takeuchi, O.; Standley, D.M.; Kumagai, Y.; Kawagoe, T.; Miyake, T.; Satoh, T.; Kato, H.; Tsujimura, T.; Nakamura, H.; et al. Zc3h12a is an RNase essential for controlling immune responses by regulating mRNA decay. *Nature* 2009, 458, 1185–1190. [CrossRef] [PubMed]

105. Qin, Z.; Kearney, P.; Plaisance, K.; Parsons, C.H. Pivotal advance: Kaposi’s sarcoma-associated herpesvirus (KSHV)-encoded microRNA specifically induce IL-6 and IL-10 secretion by macrophages and monocytes. *J. Leukoc. Biol.* 2010, 87, 25–34. [CrossRef] [PubMed]

106. Skalsky, R.L.; Samols, M.A.; Plaisance, K.B.; Boss, I.W.; Riva, A.; Lopez, M.C.; Baker, H.V.; Renne, R. Kaposi’s sarcoma-associated herpesvirus encodes an ortholog of miR-155. *J. Virol.* 2007, 81, 12836–12845. [CrossRef] [PubMed]

107. Gottwein, E.; Mukherjee, N.; Sachsse, C.; Frenzel, C.; Majoros, W.H.; Chi, J.T.; Braich, R.; Manoharan, M.; Soutschek, J.; Ohler, U.; et al. A viral microRNA functions as an orthologue of cellular miR-155. *Nature* 2007, 450, 1096–1099. [CrossRef] [PubMed]

108. Gottwein, E.; Corcoran, D.L.; Mukherjee, N.; Skalsky, R.L.; Hafner, M.; Nusbaum, J.D.; Shamulailatpam, P.; Love, C.L.; Dave, S.S.; Tuschl, T.; et al. Viral microRNA targetome of KSHV-infected primary effusion lymphoma cell lines. *Cell Host Microbe* 2011, 10, 515–526. [CrossRef] [PubMed]

109. Manzano, M.; Shamulailatpam, P.; Raja, A.N.; Gottwein, E. Kaposi’s sarcoma-associated herpesvirus encodes a mimic of cellular miR-23. *J. Virol.* 2013, 87, 11821–11830. [CrossRef] [PubMed]

110. Lei, X.; Zhu, Y.; Jones, T.; Bai, Z.; Huang, Y.; Gao, S.J. A Kaposi’s sarcoma-associated herpesvirus microRNA and its variants target the transforming growth factor beta pathway to promote cell survival. *J. Virol.* 2012, 86, 11698–11711. [CrossRef] [PubMed]

111. Qin, Z.; Freitas, E.; Sullivan, R.; Mohan, S.; Bacelieri, R.; Branch, D.; Romano, M.; Kearney, P.; Oates, J.; Plaisance, K.; et al. Upregulation of xCT by KSHV-encoded microRNAs facilitates KSHV dissemination and persistence in an environment of oxidative stress. *PLoS Pathog.* 2010, 6, e1000742. [CrossRef] [PubMed]

112. Liang, D.; Gao, Y.; Lin, X.; He, Z.; Zhao, Q.; Deng, Q.; Lan, K. A human herpesvirus microRNA attenuates interferon signaling and contributes to maintenance of viral latency by targeting IKKepsilon. *Cell Res.* 2011, 21, 793–806. [CrossRef] [PubMed]

113. Boss, I.W.; Nadeau, P.E.; Abbott, J.R.; Yang, Y.; Mergia, A.; Renne, R. A Kaposi’s sarcoma-associated herpesvirus-encoded ortholog of microRNA miR-155 induces human splenic B-cell expansion in NOD/LtSz-scid IL2Rgamma null mice. *J. Virol.* 2011, 85, 9877–9886. [CrossRef] [PubMed]

114. Liu, Y.; Sun, R.; Lin, X.; Liang, D.; Deng, Q.; Lan, K. Kaposi’s sarcoma-associated herpesvirus-encoded microRNA miR-K12-11 attenuates transforming growth factor beta signaling through suppression of SMAD5. *J. Virol.* 2012, 86, 1372–1381. [CrossRef] [PubMed]

115. Mashima, R. Physiological roles of miR-155. *Immunology* 2015, 145, 323–333. [CrossRef] [PubMed]

116. Duan, F.; Liao, J.; Huang, Q.; Nie, Y.; Wu, K. HSV-1 miR-H6 inhibits HSV-1 replication and IL-6 expression in human corneal epithelial cells in vitro. *Clin. Dev. Immunol.* 2012, 2012, 192791. [CrossRef] [PubMed]
117. Tang, S.; Patel, A.; Krause, P.R. Novel less-abundant viral microRNAs encoded by herpes simplex virus 2 latency-associated transcript and their roles in regulating ICP34.5 and ICP0 mRNAs. J. Virol. 2009, 83, 1433–1442. [CrossRef] [PubMed]

118. Samaniego, L.A.; Wu, N.; DeLuca, N.A. The herpes simplex virus immediate-early protein ICP0 affects transcription from the viral genome and infected-cell survival in the absence of ICP4 and ICP27. J. Virol. 1997, 71, 4614–4625. [PubMed]

119. Tang, S.; Bertke, A.S.; Patel, A.; Wang, K.; Cohen, J.I.; Krause, P.R. An acutely and latently expressed herpes simplex virus 2 viral microRNA inhibits expression of ICP34.5, a viral neurovirulence factor. Proc. Natl. Acad. Sci. USA 2008, 105, 10931–10936. [CrossRef] [PubMed]

120. Umbach, J.L.; Kramer, M.F.; Jurak, I.; Karnowski, H.W.; Coen, D.M.; Cullen, B.R. MicroRNAs expressed by herpes simplex virus 1 during latent infection regulate viral mRNAs. Nature 2008, 454, 780–783. [CrossRef] [PubMed]

121. Du, T.; Han, Z.; Zhou, G.; Roizman, B. Patterns of accumulation of miRNAs encoded by herpes simplex virus during productive infection, latency, and on reactivation. Proc. Natl. Acad. Sci. USA 2015, 112, E49–55. [CrossRef] [PubMed]

122. Grey, F.; Meyers, H.; White, E.A.; Spector, D.H.; Nelson, J. A human cytomegalovirus-encoded microRNA regulates expression of multiple viral genes involved in replication. PLoS Pathog. 2007, 3, e163. [CrossRef] [PubMed]

123. Lo, A.K.; To, K.F.; Lo, K.W.; Lung, R.W.; Hui, J.W.; Liao, G.; Hayward, S.D. Modulation of LMP1 protein expression by EBV-encoded microRNAs. Proc. Natl. Acad. Sci. USA 2007, 104, 16164–16169. [CrossRef] [PubMed]

124. Lung, R.W.; Tong, J.H.; Sung, Y.M.; Leung, P.S.; Ng, D.C.; Chau, S.L.; Chan, A.W.; Ng, E.K.; Lo, K.W.; To, K.F. Modulation of LMP2A expression by a newly identified Epstein-Barr virus-encoded microRNA miR-BART22. Neoplasia 2009, 11, 1174–1184. [CrossRef] [PubMed]

125. Choi, I.K.; Wang, Z.; Ke, Q.; Hong, M.; Qian, Y.; Zhao, X.; Liu, Y.; Kim, H.J.; Ritz, J.; Cantor, H.; et al. Signaling by the Epstein-Barr virus LMP1 protein induces potent cytotoxic CD4(+) and CD8(+) T cell responses. Proc. Natl. Acad. Sci. USA 2018, 115, E686–E695. [CrossRef] [PubMed]

126. Verhoeven, R.J.; Tong, S.; Zhang, G.; Zong, J.; Chen, Y.; Jin, D.Y.; Chen, M.R.; Pan, J.; Chen, H. NF-κB Signaling Regulates Expression of Epstein-Barr Virus BART MicroRNAs and Long Noncoding RNAs in Nasopharyngeal Carcinoma. J. Virol. 2016, 90, 6475–6488. [CrossRef] [PubMed]

127. Qin, J.; Li, W.; Gao, S.J.; Lu, C. KSHV microRNAs: Tricks of the Devil. Trends Microbiol. 2017, 25, 648–661. [CrossRef] [PubMed]

128. Cai, X.; Lu, S.; Zhang, Z.; Gonzalez, C.M.; Damania, B.; Cullen, B.R. Kaposi’s sarcoma-associated herpesvirus expresses an array of viral microRNAs in latently infected cells. Proc. Natl. Acad. Sci. USA 2005, 102, 5570–5575. [CrossRef] [PubMed]

129. Lin, X.; Li, Z.; Renne, R.; Lieberman, P.M. Epigenetic regulation of Kaposi’s sarcoma-associated herpesvirus latency by virus-encoded microRNAs that target Rta and the cellular Rbl2-DNMT pathway. J. Virol. 2010, 84, 2697–2706. [CrossRef] [PubMed]

130. Bellare, P.; Ganem, D. Regulation of KSHV lytic switch protein expression by a virus-encoded microRNA: An evolutionary adaptation that fine-tunes lytic reactivation. Cell Host Microbe 2009, 6, 570–575. [CrossRef] [PubMed]

131. Lu, C.C.; Li, Z.; Chu, C.Y.; Peng, J.; Fung, J.; Sun, R.; Rana, T.M. MicroRNAs encoded by Kaposi’s sarcoma-associated herpesvirus regulate viral life cycle. EMBO Rep. 2010, 11, 784–790. [CrossRef] [PubMed]

132. Lu, F.; Stedman, W.; Yousef, M.; Renne, R.; Lieberman, P.M. Epigenetic regulation of Kaposi’s sarcoma-associated herpesvirus latency by virus-encoded microRNAs that target Rta and the cellular Rbl2-DNMT pathway. J. Virol. 2010, 84, 2697–2706. [CrossRef] [PubMed]

133. Meshesha, M.K.; Bentwich, Z.; Solomon, S.A.; Avni, Y.S. In vivo expression of human cytomegalovirus (HCMV) microRNAs during latency. Gene 2016, 575, 101–107. [CrossRef] [PubMed]

134. Imperiale, M.J. The Human Polyomaviruses: An Overview. In Human Polyomaviruses; Khalili, K., Stoner, G.L., Eds.; Wiley-Liss, Inc.: New York, NY, USA, 2002; pp. 53–71.

135. Lagokie, O.; Trigarette, L.; Stuyver, L.J. The miRNA world of polyomaviruses. Virol. J. 2013, 10, 268. [CrossRef] [PubMed]
136. Moens, U.; Calvignac-Spencer, S.; Lauber, C.; Ramqvist, T.; Feltkamp, M.C.W.; Daughtery, M.D.; Verschoor, E.J.; Ehlers, B.; Consortium, I.R. ICTV Virus Taxonomy Profile: Polyomaviridae. J. Gen. Virol. 2017, 98, 1159–1160. [CrossRef] [PubMed]

137. White, M.K.; Khalili, K. Polyomaviruses and human cancer: Molecular mechanisms underlying patterns of tumorigenesis. Virology 2004, 324, 1–16. [CrossRef] [PubMed]

138. Gu, R.; Zhang, Z.; DeCerbo, J.N.; Carmichael, G.G. Gene regulation by sense-antisense overlap of polyadenylation signals. RNA 2009, 15, 1154–1163. [CrossRef] [PubMed]

139. Seo, G.J.; Fink, L.H.; O’Hara, B.; Atwood, W.J.; Sullivan, C.S. Evolutionarily conserved function of a viral microRNA. J. Virol. 2008, 82, 9823–9828. [CrossRef] [PubMed]

140. Sullivan, C.S.; Grundhoff, A.T.; Tevethia, S.; Pipas, J.M.; Ganem, D. SV40-encoded microRNAs regulate viral gene expression and reduce susceptibility to cytotoxic T cells. Nature 2005, 435, 682–686. [CrossRef] [PubMed]

141. Sullivan, C.S.; Sung, C.K.; Pack, C.D.; Grundhoff, A.; Lukacher, A.E.; Benjamin, T.L.; Ganem, D. Murine Polyomavirus encodes a microRNA that cleaves early RNA transcripts but is not essential for experimental infection. Virology 2009, 387, 157–167. [CrossRef] [PubMed]

142. Broekema, N.M.; Imperiale, M.J. miRNA regulation of BK polyomavirus replication during early infection. Proc. Natl. Acad. Sci. USA 2013, 110, 8200–8205. [CrossRef] [PubMed]

143. Tian, Y.C.; Li, Y.J.; Chen, H.C.; Wu, H.H.; Weng, C.H.; Chen, Y.C.; Lee, C.C.; Chang, M.Y.; Hsu, H.H.; Yen, T.H.; et al. Polyomavirus BK-encoded microRNA suppresses autoregulation of viral replication. Biochem. Biophys. Res. Commun. 2014, 447, 543–549. [CrossRef] [PubMed]

144. Bauman, Y.; Mandelboim, O. MicroRNA based immunoevasion mechanism of human polyomaviruses. RNA Biol. 2011, 8, 591–594. [CrossRef] [PubMed]

145. Bauman, Y.; Nachmani, D.; Vitenshtein, A.; Tsukerman, P.; Drayman, N.; Stern-Ginossar, N.; Lankry, D.; Gruda, R.; Mandelboim, O. An identical miRNA of the human JC and BK polyoma viruses targets the stress-induced ligand ULBP3 to escape immune elimination. Cell Host Microbe 2011, 9, 93–102. [CrossRef] [PubMed]

146. Burke, J.M.; Bass, C.R.; Kincaid, R.P.; Ulug, E.T.; Sullivan, C.S. The Murine Polyomavirus MicroRNA Locus Is Required To Promote Viruria during the Acute Phase of Infection. J. Virol. 2018, 92. [CrossRef] [PubMed]

147. You, X.; Zhang, Z.; Fan, J.; Cui, Z.; Zhang, X.E. Functionally orthologous viral and cellular microRNAs studied by a novel dual-fluorescent reporter system. PLoS ONE 2012, 7, e36157. [CrossRef] [PubMed]

148. Garkavtsev, I.; Kozin, S.V.; Chernova, O.; Xu, L.; Winkler, F.; Brown, E.; Barnett, G.H.; Jain, R.K. The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis. Nature 2004, 428, 328–332. [CrossRef] [PubMed]

149. Coles, A.H.; Jones, S.N. The ING gene family in the regulation of cell growth and tumorigenesis. J. Cell. Physiol. 2009, 218, 45–57. [CrossRef] [PubMed]

150. Shiseki, M.; Nagashima, M.; Pedeurx, R.M.; Kitahama-Shiseki, M.; Miura, K.; Okamura, S.; Onogi, H.; Higashimoto, Y.; Appella, E.; Yokota, J.; et al. p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis. Proc. Natl. Acad. Sci. USA 2009, 106, 21849–21854. [CrossRef] [PubMed]

151. Li, S.; Zeng, A.; Hu, Q.; Yan, W.; Liu, Y.; You, Y. miR-423-5p contributes to a malignant phenotype and asbestos exposure and malignant mesothelioma: Systematic review and qualitative meta-analysis. Oncotarget 2016, 7, 58606–58637. [CrossRef] [PubMed]

152. Sevinc, E.D.; Egeli, U.; Cecener, G.; Tezcan, G.; Tunca, B.; Gokgoz, S.; Tasdelen, I.; Tolunay, S.; Evrensel, T. Association of miR-1266 with recurrence/metastasis potential in estrogen receptor positive breast cancer patients. Asian Pac. J. Cancer Prev. 2015, 16, 291–297. [CrossRef] [PubMed]

153. Chen, L.; Lu, M.H.; Zhang, D.; Hao, N.B.; Fan, Y.H.; Wu, Y.Y.; Wang, S.M.; Xie, R.; Fang, D.C.; Zhang, H.; et al. miR-1207-5p and miR-1266 suppress gastric cancer growth and invasion by targeting telomerase reverse transcriptase. Cell Death Dis. 2014, 5, e1034. [CrossRef] [PubMed]

154. Zhang, X.; Ren, D.; Wu, X.; Lin, X.; Ye, L.; Lin, C.; Wu, S.; Zhu, J.; Peng, X.; Song, L. miR-1266 Contributes to Pancreatic Cancer Progression and Chemoresistance by the STAT3 and NF-kB Signaling Pathways. Mol. Ther. Nucleic Acids 2018, 11, 142–158. [CrossRef] [PubMed]
Viruses 2018, 10, 440

156. Wang, Q.; Li, D.C.; Li, Z.F.; Liu, C.X.; Xiao, Y.M.; Zhang, B.; Li, X.D.; Zhao, J.; Chen, L.P.; Xing, X.M.; et al. Upregulation of miR-27a contributes to the malignant transformation of human bronchial epithelial cells induced by SV40 small T antigen. Oncogene 2011, 30, 3875–3886. [CrossRef] [PubMed]

157. Lerner, M.; Lundgren, J.; Akhoondi, S.; Jahn, A.; Ng, H.F.; Akbari Moqadam, F.; Oude Vrielink, J.A.; Agami, R.; Den Boer, M.L.; Grander, D.; et al. MiRNA-27a controls FBW7/hCDC4-dependent cyclin E degradation and cell cycle progression. Cell Cycle 2011, 20, 2172–2183. [CrossRef] [PubMed]

158. Xie, N.; Cui, H.; Banerjee, S.; Tan, Z.; Salomao, R.; Fu, M.; Abraham, E.; Thannickal, V.J.; Liu, G. miR-27a regulates inflammatory response of macrophages by targeting IL-10. J. Immunol. 2014, 193, 327–334. [CrossRef] [PubMed]

159. Park, J.L.; Kim, M.; Song, K.S.; Kim, Y.S. Cell-Free miR-27a, a Potential Diagnostic and Prognostic Biomarker for Gastric Cancer. Genom. Inform. 2015, 13, 70–75. [CrossRef] [PubMed]

160. Nisole, S.; Saib, A. Early steps of retrovirus replicative cycle. Retrovirology 2004, 1, 9. [CrossRef] [PubMed]

161. Greene, W.C.; Peterlin, B.M. Charting HIV’s remarkable voyage through the cell: Basic science as a passport to future therapy. Nat. Med. 2002, 8, 673–680. [CrossRef] [PubMed]

162. Huang, J.; Wang, F.; Argyris, E.; Chen, K.; Liang, Z.; Tian, H.; Huang, W.; Squires, K.; Verlinghieri, G.; Zhang, H. Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes. Nat. Med. 2007, 13, 1241–1247. [CrossRef] [PubMed]

163. Wang, X.; Ye, L.; Hou, W.; Zhou, Y.; Wang, Y.J.; Metzger, D.S.; Ho, W.Z. Cellular microRNA expression correlates with susceptibility of monocytes/macrophages to HIV-1 infection. Blood 2009, 113, 671–674. [CrossRef] [PubMed]

164. Balasubramaniam, M.; Pandhare, J.; Dash, C. Are microRNAs Important Players in HIV-1 Infection? An Update. Viruses 2018, 10, 110. [CrossRef] [PubMed]

165. Chiang, K.; Liu, H.; Rice, A.P. miR-132 enhances HIV-1 replication. Virology 2013, 438, 1–4. [CrossRef] [PubMed]

166. Klein, M.E.; Lioy, D.T.; Ma, L.; Impey, S.; Mandel, G.; Goodman, R.H. Homeostatic regulation of MeCP2 expression by a CREB-induced microRNA. Nat. Neurosci. 2007, 10, 1513–1514. [CrossRef] [PubMed]

167. Alvarez-Saavedra, M.; Antoun, G.; Yanagiya, A.; Oliva-Hernandez, R.; Cornejo-Palma, D.; Perez-Iratxeta, C.; Sonenberg, N.; Cheng, H.Y. miRNA-132 orchestrates chromatin remodeling and translational control of the circadian clock. Hum. Mol. Genet. 2011, 20, 731–751. [CrossRef] [PubMed]

168. Omoto, S.; Ito, M.; Tsutsumi, Y.; Ichikawa, Y.; Okuyama, H.; Brisibe, E.A.; Saksena, N.K.; Fujii, Y.R. HIV-1 nef suppression by virally encoded microRNA. Retrovirology 2004, 1, 44. [CrossRef] [PubMed]

169. Omoto, S.; Fujii, Y.R. Regulation of human immunodeficiency virus 1 transcription by nef microRNA. J. Gen. Virol. 2005, 86, 751–755. [CrossRef] [PubMed]

170. Ouellet, D.L.; Plante, I.; Landry, P.; Barat, C.; Janelle, M.E.; Flamand, L.; Tremblay, M.J.; Provost, P. Identification of functional microRNAs released through asymmetrical processing of HIV-1 TAR element. Nucleic Acids Res. 2008, 36, 2353–2365. [CrossRef] [PubMed]

171. Klase, Z.; Winograd, R.; Davis, J.; Carpio, L.; Hildreth, R.; Heydarian, M.; Fu, S.; McCaffrey, T.; Meiri, E.; Ayash-Rashkovsky, M.; et al. HIV-1 TAR miRNA protects against apoptosis by altering cellular gene expression. Retrovirology 2009, 6, 18. [CrossRef] [PubMed]

172. Kaul, D.; Aihlawat, A.; Gupta, S.D. HIV-1 genome-encoded hiv1-mir-H1 impairs cellular responses to infection. Mol. Cell Biochem. 2009, 323, 143–148. [CrossRef] [PubMed]

173. Bennasser, Y.; Le, S.Y.; Benkirane, M.; Jeang, K.T. Evidence that HIV-1 encodes an siRNA and a suppressor of RNA silencing. Immunity 2005, 22, 607–619. [CrossRef] [PubMed]

174. Bennasser, Y.; Jeang, K.T. HIV-1 Tat interaction with Dicer: Requirement for RNA. Retrovirology 2006, 3, 95. [CrossRef] [PubMed]

175. Sardo, L.; Vakil, P.R.; Elbezanti, W.; El-Sayed, A.; Klase, Z. The inhibition of microRNAs by HIV-1 Tat suppresses beta catenin activity in astrocytes. Retrovirology 2016, 13, 25. [CrossRef] [PubMed]

176. Haase, A.D.; Jaskiewicz, L.; Zhang, H.; Laine, S.; Sack, R.; Gatignol, A.; Filipowicz, W. TRBP, a regulator of cellular PKR and HIV-1 virus expression, interacts with Dicer and functions in RNA silencing. EMBO Rep. 2005, 6, 961–967. [CrossRef] [PubMed]

177. Daniels, S.M.; Sinck, L.; Ward, N.J.; Melendez-Pena, C.E.; Scarborough, R.J.; Azar, I.; Rance, E.; Daher, A.; Pang, K.M.; Rossi, J.J.; et al. HIV-1 RRE RNA acts as an RNA silencing suppressor by competing with TRBP-bound siRNAs. RNA Biol. 2015, 12, 123–135. [CrossRef] [PubMed]
178. Rausch, J.W.; Le Grice, S.F. HIV Rev Assembly on the Rev Response Element (RRE): A Structural Perspective. *Viruses* 2015, 7, 3053–3075. [CrossRef] [PubMed]

179. Lecellier, C.H.; Dunoyer, P.; Arak, K.; Lehmann-Che, J.; Eyquem, S.; Himber, C.; Saib, A.; Voinnet, O. A cellular micro RNA mediates antiviral defense in human cells. *Science* 2005, 308, 557–560. [CrossRef] [PubMed]

180. Khodakaram-Tafti, A.; Farjanikish, G.H. Persistent bovine viral diarrhea virus (BVDV) infection in cattle herds. *Iran J. Vet. Res.* 2017, 18, 154–163. [PubMed]

181. Scheel, T.K.; Luna, J.M.; Liniger, M.; Nishiuchi, E.; Rozen-Gagnon, K.; Shlomai, A.; Auray, G.; Gerber, M.; Fak, J.; Keller, I.; et al. A Broad RNA Virus Survey Reveals Both miRNA Dependence and Functional Sequestration. *Cell Host Microbe* 2016, 19, 409–423. [CrossRef] [PubMed]

182. Moes, L.; Wirth, M. The internal initiation of translation in bovine viral diarrhea virus RNA depends on the presence of an RNA pseudoknot upstream of the initiation codon. *Virol. J.* 2007, 4, 124. [CrossRef] [PubMed]

183. Austermann-Busch, S.; Becher, P. RNA structural elements determine frequency and sites of nonhomologous recombination in an animal plus-strand RNA virus. *J. Virol.* 2012, 86, 7393–7402. [CrossRef] [PubMed]

184. Schult, P.; Roth, H.; Adams, R.L.; Mas, C.; Imbert, L.; Orlik, C.; Ruggieri, A.; Pyle, A.M.; Lohmann, V. microRNA-122 amplifies hepatitis C virus translation by shaping the structure of the internal ribosomal entry site. *Nat. Commun.* 2018, 9, 2613. [CrossRef] [PubMed]

185. Isken, O.; Grassmann, C.W.; Sarisky, R.T.; Kann, M.; Zhang, S.; Grosse, F.; Kao, P.N.; Behrens, S.E. Members of the NF90/NFAR protein group are involved in the life cycle of a positive-strand RNA virus. *EMBO J.* 2003, 22, 5655–5665. [CrossRef] [PubMed]

186. Pankraz, A.; Thiel, H.J.; Becher, P. Essential and nonessential elements in the 3′ nontranslated region of Bovine viral diarrhea virus. *J. Virol.* 2005, 79, 9119–9127. [CrossRef] [PubMed]

187. Scheel, T.K.H.; Moore, M.J.; Luna, J.M.; Nishiuchi, E.; Fak, J.; Darnell, R.B.; Rice, C.M. Global mapping of miRNA-target interactions in cattle (Bos taurus). *Sci. Rep.* 2017, 7, 8190. [CrossRef] [PubMed]

188. Mogilyansky, E.; Rigoutsos, I. The miR-17/92 cluster: A comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease. *Cell Death Differ.* 2013, 20, 1603–1614. [CrossRef] [PubMed]

189. Lozoya, T.; Dominguez, F.; Romero-Ruiz, A.; Steffani, L.; Martinez, S.; Monterde, M.; Ferri, B.; Nunez, M.J.; AinhoaRomero, E.; Zamora, O.; et al. The Lin28/Let-7 system in early human embryonic tissue and ectopic pregnancy. *PLoS ONE* 2014, 9, e87698. [CrossRef] [PubMed]

190. Gilchrist, G.C.; Tscherner, A.; Nalpathamkalam, T.; Merico, D.; LaMarre, J. MicroRNA Expression during HIV Rev Assembly on the Rev Response Element (RRE): A Structural Perspective. *J. Virol.* 2014, 88, 198–201. [CrossRef] [PubMed]

191. Chang, J.; Nicolas, E.; Marks, D.; Sander, C.; Lerro, A.; Buendia, M.A.; Xu, C.; Mason, W.S.; Moloshok, T.; Bort, R.; et al. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. *RNA Biol.* 2004, 1, 106–113. [CrossRef] [PubMed]

192. Mendell, J.T. miRiad roles for the miR-17-92 cluster in development and disease. *Cell* 2008, 133, 217–222. [CrossRef] [PubMed]

193. Chase, C.C. The impact of BVDV infection on adaptive immunity. *Biologicals* 2013, 41, 52–60. [CrossRef] [PubMed]

194. Chang, J.; Nicolas, E.; Marks, D.; Sander, C.; Lerro, A.; Buendia, M.A.; Xu, C.; Mason, W.S.; Moloshok, T.; Bort, R.; et al. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. *RNA Biol.* 2004, 1, 106–113. [CrossRef] [PubMed]

195. Lagos-Quintana, M.; Rauhut, R.; Yalcin, A.; Meyer, J.; Lendeckel, W.; Tuschl, T. Identification of tissue-specific microRNAs from mouse. *Curr. Biol.* 2002, 12, 735–739. [CrossRef] [PubMed]

196. Jopling, C. Liver-specific microRNA-122: Biogenesis and function. *RNA Biol.* 2012, 9, 137–142. [CrossRef] [PubMed]

197. Lewis, A.P.; Jopling, C.L. Regulation and biological function of the liver-specific miR-122. *Biochem. Soc. Trans.* 2010, 38, 1553–1557. [CrossRef] [PubMed]

198. Jopling, C.L.; Yi, M.; Lancaster, A.M.; Lemon, S.M.; Sarnow, P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. *Science* 2005, 309, 1577–1581. [CrossRef] [PubMed]

199. Norman, K.L.; Sarnow, P. Modulation of hepatitis C virus RNA abundance and the isoprenoid biosynthesis pathway by microRNA miR-122 involves distinct mechanisms. *J. Virol.* 2010, 84, 666–670. [CrossRef] [PubMed]
200. Zhang, C.; Huys, A.; Thibault, P.A.; Wilson, J.A. Requirements for human Dicer and TRBP in microRNA-122 regulation of HCV translation and RNA abundance. *Virology* 2012, 433, 479–488. [CrossRef] [PubMed]

201. Randall, G.; Panis, M.; Cooper, J.D.; Tellinghuisen, T.L.; Sukhodolets, K.E.; Pfeffer, S.; Landthaler, M.; Landgraf, P.; Kan, S.; Lindenbach, B.D.; et al. Cellular cofactors affecting hepatitis C virus infection and replication. *Proc. Natl. Acad. Sci. USA* 2007, 104, 12884–12889. [CrossRef] [PubMed]

202. Machlin, E.S.; Sarnow, P.; Sagan, S.M. Masking the 5′ terminal nucleotides of the hepatitis C virus genome by an unconventional microRNA-target RNA complex. *Proc. Natl. Acad. Sci. USA* 2011, 108, 3193–3198. [CrossRef] [PubMed]

203. Adams, R.L.; Pirakitikul, N.; Pyle, A.M. Functional RNA structures throughout the Hepatitis C Virus genome. *Curr. Opin. Virol.* 2017, 24, 79–86. [CrossRef] [PubMed]

204. Amador-Canizares, Y.; Bernier, A.; Wilson, J.A.; Sagan, S.M. miR-122 does not impact recognition of the hepatitis C virus by innate sensors of RNA but rather protects the 5′ end from the cellular pyrophosphatases, DOM3Z and DUSP11. *Nucleic Acids Res.* 2018, 46, 5139–5158. [CrossRef] [PubMed]

205. Kincaid, R.P.; Lam, V.L.; Chirayil, R.P.; Randall, G.; Sullivan, C.S. RNA triphosphatase DUSP11 enables exoribonuclease XRN-mediated restriction of hepatitis C virus. *Proc. Natl. Acad. Sci. USA* 2018, 115, 8197–8202. [CrossRef] [PubMed]

206. Jinek, M.; Coyle, S.M.; Doudna, J.A. Coupled 5′-nucleotide recognition and processivity in Xrn1-mediated mRNA decay. *Mol. Cell* 2011, 41, 600–608. [CrossRef] [PubMed]

207. Stevens, A.; Poole, T.L. 5′-exonuclease-2 of Saccharomyces cerevisiae. Purification and features of ribonuclease activity with comparison to 5′-exonuclease-1. *J. Biol. Chem.* 1995, 270, 16063–16069. [CrossRef] [PubMed]

208. Sedano, C.D.; Sarnow, P. Hepatitis C virus subverts liver-specific miR-122 to protect the viral genome from exoribonuclease Xrn2. *Cell Host Microbe* 2014, 16, 257–264. [CrossRef] [PubMed]

209. Zhou, X.; Michel, J.J.; Zhang, L.; Ding, B.; Lunney, J.K.; Liu, B.; Jiang, Z. Interferon induced IFIT family genes to microRNA-122 regulation of hepatitis C virus replication. *Int. J. Biol. Sci.* 2015, 9, 200–208. [CrossRef] [PubMed]

210. Li, Y.; Yamane, D.; Lemon, S.M. Dissecting the roles of the 5′-UTR RNA to stabilize and promote viral RNA accumulation. *Nucleic Acids Res.* 2018, 46, 6330–6343. [CrossRef] [PubMed]

211. Locker, N.; Easton, L.E.; Lukavsky, P.J. HCV and CSFV IRES domain II mediate eIF2 release during 80S ribosome assembly. *EMBO J.* 2007, 26, 795–805. [CrossRef] [PubMed]

212. Diaz-Toledano, R.; Ariza-Mateos, A.; Birk, A.; Martinez-Garcia, B.; Gomez, J. In vitro characterization of a miR-122-sensitive double-helical switch element in the 5′ region of hepatitis C virus RNA. *Nucleic Acids Res.* 2009, 37, 5498–5510. [CrossRef] [PubMed]

213. Meijer, H.A.; Kong, Y.W.; Lu, W.T.; Wilczynska, A.; Spriggs, R.V.; Robinson, S.W.; Godfrey, J.D.; Willis, A.E.; Bushell, M. Translational repression and elF4A2 activity are critical for microRNA-mediated gene regulation. *Science* 2013, 340, 82–85. [CrossRef] [PubMed]

214. Ahmed, C.S.; Winlow, P.L.; Parsons, A.L.; Jopling, C.L. Eukaryotic translation initiation factor 4AII contributes to microRNA-122 regulation of hepatitis C virus replication. *Nucleic Acids Res.* 2018, 46, 6330–6343. [CrossRef] [PubMed]

215. Smith, R.M.; Walton, C.M.; Wu, C.H.; Wu, G.Y. Secondary structure and hybridization accessibility of hepatitis C virus 3′-terminal sequences. *J. Virol.* 2002, 76, 9563–9574. [CrossRef] [PubMed]

216. Friebe, P.; Bartenschlager, R. Role of RNA structures in genome terminal sequences of the hepatitis C virus for replication and assembly. *J. Virol.* 2009, 83, 11989–11995. [CrossRef] [PubMed]

217. Hopcraft, S.E.; Azarm, K.D.; Israelow, B.; Leveque, N.; Schwarz, M.C.; Hsu, T.H.; Chambers, M.T.; Sourisseau, M.; Semler, B.L.; Evans, M.J. Viral Determinants of miR-122-Independent Hepatitis C Virus Replication. *mSphere* 2016, 1. [CrossRef] [PubMed]

218. Ono, C.; Fukuhara, T.; Motooka, D.; Nakamura, S.; Okuzaki, D.; Yamamoto, S.; Tamura, T.; Mori, H.; Sato, A.; Uemura, K.; et al. Characterization of miR-122-independent propagation of HCV. *PLoS Pathog.* 2017, 13, e1006374. [CrossRef] [PubMed]

219. Amador-Cañizares, Y.; Panigrahi, M.; Huys, A.; Kundert, R.D.; Adams, H.M.; Schinold, M.J.; Wilson, J.A. miR-122, small RNA annealing and sequence mutations alter the predicted structure of the Hepatitis C virus 5′ UTR RNA to stabilize and promote viral RNA accumulation. *Nucleic Acids Res.* 2018. [CrossRef] [PubMed]
220. Luna, J.M.; Scheel, T.K.; Danino, T.; Shaw, K.S.; Mele, A.; Fak, J.J.; Nishiuchi, E.; Takacs, C.N.; Catanese, M.T.; de Jong, Y.P.; et al. Hepatitis C virus RNA functionally sequesters miR-122. *Cell* 2015, 160, 1099–1110. [CrossRef] [PubMed]

221. Dong, T.; Yan, Y.; Chai, H.; Chen, S.; Xiong, X.; Sun, D.; Yu, Y.; Deng, L.; Cheng, F. Pyruvate kinase M2 affects liver cancer cell behavior through up-regulation of HIF-1alpha and Bcl-xL in culture. *Biomed. Pharmacother.* 2015, 69, 277–284. [CrossRef] [PubMed]

222. Li, J.; Ghazwani, M.; Zhang, Y.; Lu, J.; Li, J.; Fan, J.; Gandhi, C.R.; Li, S. miR-122 regulates collagen production via targeting hepatic stellate cells and suppressing P4HA1 expression. *J. Hepatol.* 2013, 58, 522–528. [CrossRef] [PubMed]

223. Jung, C.J.; Iyengar, S.; Blahnik, K.R.; Ajuha, T.P.; Jiang, J.X.; Farnham, P.J.; Zern, M. Epigenetic modulation of miR-122 facilitates human embryonic stem cell self-renewal and hepatocellular carcinoma proliferation. *PLoS ONE* 2011, 6, e27740. [CrossRef] [PubMed]

224. Hsu, S.H.; Wang, B.; Kota, J.; Yu, J.; Costinean, S.; Kutay, H.; Yu, L.; Bai, S.; La Perle, K.; Chivukula, R.R.; et al. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. *J. Clin. Investig.* 2012, 122, 2871–2883. [CrossRef] [PubMed]

225. Zeisel, M.B.; Pfeffer, S.; Baumert, T.F. miR-122 acts as a tumor suppressor in hepatocarcinogenesis in vivo. *J. Hepatol.* 2013, 58, 821–823. [CrossRef] [PubMed]

226. Sagan, S.M.; Sarnow, P.; Wilson, J.A. Modulation of GB Virus B RNA Abundance by MicroRNA-122: Dependence on and Escape from MicroRNA-122 Restriction. *J. Virol.* 2013, 87, 7338–7347. [CrossRef] [PubMed]

227. Kapoor, A.; Simmonds, P.; Gerold, G.; Qaisar, N.; Jain, K.; Henriquez, J.A.; Firth, C.; Hirschberg, D.L.; Rice, C.M.; Shields, S.; et al. Characterization of a canine homolog of hepatitis C virus. *Proc. Natl. Acad. Sci. USA* 2011, 108, 11608–11613. [CrossRef] [PubMed]

228. Kapoor, A.; Simmonds, P.; Scheel, T.K.; Hjelle, B.; Cullen, J.M.; Burbelo, P.D.; Chauhan, L.V.; Duraisamy, R.; Sanchez Leon, M.; Jain, K.; et al. Identification of rodent homologs of hepatitis C virus and pegiviruses. *MBio* 2013, 4, e00216–e00213. [CrossRef] [PubMed]

229. Baron, A.L.; Schoeniger, A.; Becher, P.; Baechlein, C. Mutational Analysis of the Bovine Hepacivirus Internal Ribosome Entry Site. *J. Virol.* 2018, 92, 1974–17. [CrossRef] [PubMed]

230. Yu, Y.; Scheel, T.K.; Luna, J.M.; Chung, H.; Nishiuchi, E.; Scull, M.A.; Echeverria, N.; Ricardo-Lax, I.; Kapoor, A.; Lipkin, I.W.; et al. miRNA independent hepacivirus variants suggest a strong evolutionary pressure to maintain miR-122 dependence. *PLoS Pathog.* 2017, 13, e1006694. [CrossRef] [PubMed]

231. Trobaugh, D.W.; Klimenti, W.B. MicroRNA Regulation of RNA Virus Replication and Pathogenesis. *Trends Mol. Med.* 2017, 23, 80–93. [CrossRef] [PubMed]

© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).